<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/256470-alpha-ketoamide-derivative-and-production-method-and-use-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:31:04 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 256470:ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory aclivity.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>DESCRIPTION<br>
ALPHα-ketoamide DERIVATIVE, AND PRODUCTION METHOD AND USE<br>
THEREOF<br>
Technical Field<br>
The present invention relates to a novel α-ketoamide<br>
derivative having calpain inhibitory activity. Also, the<br>
present invention relates to a medicament comprising the novel<br>
1379/KOLNP/2006<br>
α-ketoamide derivative.<br>
Background Art<br>
Calpain is one of the intracellular proteases<br>
ubiquitously present in a living body, which is activated by<br>
Ca2+. It has been elucidated to this day that abnormal<br>
activation of calpain is involved in various diseases such as<br>
cerebral apoplexy, subarachnoid hemorrhage, Alzheimer's<br>
disease, ischemic disease, muscular dystrophy, cataract,<br>
platelet aggregation disorder, arthritis and the like (see<br>
Non-patent literature 1).<br>
On the other hand, it has been reported that a calpain<br>
inhibitor is effective for maintaining permeability of lens in<br>
an experimental cataract model of cultured lens and is useful<br>
as a therapeutic agent for cataract, etc. (see Non-patent<br>
literature 2, Patent literature 1).<br>
Examples of calpain inhibitors which have been so far<br>
reported are peptide halomethane derivatives, peptide<br>
diazomethane derivatives, peptidyl aldehyde derivatives,<br>
peptidyl α-ketoamide derivatives and the like (for example,<br><br>
see Patent literatures 2 to 6, Non-patent literatures 3 to 4) .<br>
(Patent literature 1) WO 93/23032<br>
(Patent literature 2) JP-B-29229/1994<br>
(Patent literature 3) EP-A-0771565<br>
(Patent literature 4) U.S. Patent No. 6057290<br>
(Patent literature 5) JP-A-147564/1998<br>
(Patent literature 6) WO 92/12140<br>
(Non-patent literature 1) Trends in Pharmacological<br>
Sciences, vol. 15, page 412, 1994<br>
(Non-patent literature 2) Current Eye Research, vol. 10,<br>
Pages 657 to. 666, 1991<br>
(Non-patent literature 3) The Biochemical Journal, vol.<br>
253, pages 751 to 758, 1988<br>
(Non-patent literature 4) Journal of Medicinal Chemistry,<br>
vol.35, pages 216 to 220, 1992<br>
Disclosure of the Invention<br>
An object of the present invention is to provide a compound<br>
having potent calpain inhibitory activity, which is well<br>
absorbed orally and exhibits durability of good blood level.<br>
The present inventors have conducted intensive studies<br>
to create a calpain inhibitor having tissue transport and<br>
absorbability, especially good oral absorbability and<br>
durability of good blood level. The present inventors designed<br>
α-ketoamide derivatives having an amphiphatic group in the<br>
molecule thereof, and found among those compounds a compound<br>
having calpain protease inhibitory activity and good oral<br>
absorbability. They have conducted further studies and thus<br>
completed the present invention.<br><br>
Namely, the present invention relates to<br>
(1) A compound represented by the formula (I)<br><br>
wherein<br>
R1 is a lower alkyl substituted by a lower alkoxy or a<br>
heterocyclic group, or a heterocyclic group;<br>
R2 is a lower alkyl optionally substituted by a phenyl;<br>
and<br>
R3 is hydrogen, a lower alkyl optionally substituted by<br>
a halogen, a lower alkoxy or a phenyl, or a fused polycyclic<br>
hydrocarbon group,<br>
(2) the compound according to the above (1), wherein the<br>
lower alkyl represented by R1 which is substituted by a lower<br>
alkoxy is a group the formula (IIa)<br><br>
in which R4 is a lower alkyl, R5 is a lower alkylene, and m is<br>
an integer of 1 to 6,<br>
( 3) the compound according to the above (1) , wherein the<br>
lower alkyl represented by R1 which is substituted by a lower<br>
alkoxy is a group of the formula (IIb)<br><br><br>
in which n is an integer of 1 to 6,<br>
(4)	the compound according to the above (1), wherein the<br>
heterocyclic group which is a substituent for the lower alkyl<br>
represented by R1 is pyridyl optionally having a lower alkyl,<br>
(5)	the compound according to the above (1), wherein the<br>
hetero atom of the heterocyclic group represented by R1 is an<br>
oxygen atom,<br>
(6)	the compound according to any one of the above (1)<br>
to ( 5) , wherein the lower alkyl represented by R3 is cyclopropyl,<br>
(7)	((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester,<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-<br>
3-(cyclopropylamino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester,<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-<br>
3-(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 8-methoxy-3,6-dioxaoctyl ester,<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-<br>
3-(cyclopropylamino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl) carbamic acid ll-methoxy-3 , 6 , 9-trioxaundecanyl<br>
ester, or ((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2, 3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-(pyridin-2-yl)ethyl ester,<br>
(8) a medicament comprising the compound according to the<br>
above (1) or (7),<br><br>
(9)	the medicament according to the above (8) , which is <br>
a calpain inhibitor,<br>
(10)	the medicament according to the above (9) , which is<br>
a therapeutic agent for a disease related to calpain, and<br>
(11)	the medicament according to the above (10), wherein<br>
the disease related to calpain is ischemic disease, immunologic<br>
disease, multiple sclerosis, Alzheimer's disease,<br>
osteoporosis, diseases caused by brain tissue damage, cataract,<br>
glaucoma, retinal disease, retinochoroiditis, posterior<br>
eyeball complications due to photocoagulation or a disease<br>
involving neovascularization.	<br>
The compound of the present invention is a calpain<br>
inhibitor which is well absorbed orally and exhibits durability<br>
of good blood level, and thus said compound can be used as an<br>
agent for prophylaxis or treatment of diseases related to<br>
 calpain such as ischemic disease, immunologic disease, multiple<br>
sclerosis, Alzheimer's disease, osteoporosis, diseases caused<br>
by brain tissue damage, cataract, glaucoma, retinochoroiditis<br>
flisease (diabetic retinopathy, retinal vein occulusion,<br>
macular degeneration, retinitis pigmentosa, hypertensive<br>
retinopathy, retinal detachment, etc.), posterior eyeball<br>
complications due to photocoagulation (e.g. macular edema,<br>
retinal detachment, optic neuritis, visual field defect, light<br>
sense defect, dyschromatopsia, etc.), a disease involving<br>
neovascularization and the like.<br>
Since the compound of the present invention has high oral<br>
absorbability, a medicament containing the compound of the<br>
present invention can be administered orally.<br><br>
In addition, the compound of the present invention has<br>
low toxicity, and thus can be used safely.<br>
Brief Description of the Accompanying Drawing <br>
Fig. 1: A graph showing viable cell count in the ganglion<br>
cell layer after 7-day retinal ischemia reperfusion in rats.<br>
Each column represents the mean ± S.E. In the graph, "Normal"<br>
means a normal group (n=8), "Control" means a control group<br>
(n=8) , and "Compound 17" means a group to which compound 17 is<br>
administered (n=9). The symbol (*) shows significant<br>
difference (P
control group.<br>
Best Mode for Carrying Out the Invention<br>
In the above formula (I), preferable examples of lower<br>
alkyl as the lower alkyl substituted by a lower alkoxy or a<br>
heterocyclic group represented by R1 include a straight or<br>
branched C1-6 alkyl group, specifically, methyl, ethyl, propyl,<br>
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,<br>
isopentyl, neopentyl, tert-pentyl, 1-methylbutyl,<br>
2-methylbutyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl,<br>
2-methylpentyl, 3-methylpenty1, 4-methylpenty1,<br>
1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl,<br>
2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl,<br>
1-ethylbutyl, 2-ethylbutyl, 1-ethyl-2-methylpropyl,<br>
1,1,2-trimethylpropyl, etc. More preferable examples of the<br>
lower alkyl for R1 include a straight or branched C2-3 alkyl group ,<br>
and the most preferable example includes ethyl.<br>
A preferable example of the lower alkoxy which is a<br><br>
substituent for the lower alkyl represented by R1 includes a<br>
C1-6 lower alkoxy such as methoxy, ethoxy, propoxy, isopropoxy,<br>
butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy,<br>
isopentyloxy, neopentyloxy, tert-pentyloxy, 1-methylbutoxy,<br>
2-methylbutoxy, 1,2-dimethylpropoxy, hexyloxy,<br>
1-methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy,<br>
4-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy,<br>
1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy,<br>
3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy,<br>
l-ethyl-2-methylpropoxy, 1,1,2-trimethylpropoxy, etc. Said<br>
alkoxy groupwhich is further substituted by said lower alkoxy<br>
may be used preferably.<br>
A preferable example of the lower alkyl represented by<br>
R1 which is substituted by a lower alkoxy includes a group the<br>
formula (Ha)<br><br>
in which R4 is a lower alkyl, R5 is a lower alkylene, and m is<br>
an integer of 1 to 6, and more preferable example includes a<br>
group of the formula (IIb)<br><br>
in which n is an integer of 1 to 6.<br>
Examples of the lower alkyl represented by R4 in the above<br>
formula (IIa) include methyl, ethyl, propyl, isopropyl, butyl,<br>
isobutyl, sec-butyl, tert-butyl, etc., preferably methyl,<br>
isopropyl or tert-butyl, and more preferably methyl.<br><br>
A preferable example of the lower alkylene represented<br>
by R5 in the above formula (IIa) includes a C1-4 alkylene,<br>
specifically methylene, ethylene, trimethylene and<br>
tetramethylene, and a more preferable example is ethylene. The<br>
lower alkylene represented by R5 may have a substituent.<br>
Examples of the substituent include methyl, ethyl, etc.<br>
In the above formula (IIa), m is an integer of 1 to 6,<br>
preferably an integer of 2 to 5. In the above formula (IIb),<br>
n is an integer of 1 to 6, preferably an integer of 1 to 5, and<br>
more preferably an integer of 2 to 5.<br>
A preferable example of the heterocyclic group which is<br>
a substituent for the lower alkyl represented by R1 includes<br>
a pyridyl optionally having a lower alkyl. Examples of the<br>
pyridyl include 2-pyridyl, 3-pyridyl and 4-pyridyl. A<br>
preferable example of the lower alkyl optionally included in<br>
said pyridyl is a C1-3 lower alkyl, specifically, methyl, ethyl,<br>
propyl, isopropyl, etc.<br>
Examples of the heterocyclic group represented by R1<br>
include 5- to 7-membered aromatic group containing one to three<br>
atom(s) identically or differently selected from the group<br>
consisting of sulfur, oxygen and nitrogen, or partially or fully<br>
reduced, saturated heterocyclic group, and specific examples<br>
thereof include furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl,<br>
imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,<br>
1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl,<br>
pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,<br>
morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl,<br>
imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl,<br>
oxazolidinyl, isoxazolidinyl, thiazolidinyl, pyrazolidinyl.<br><br>
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl,<br>
etc. , preferably saturated heterocyclic group, more preferably<br>
5- to 7-membered saturated heterocyclic group containing oxygen<br>
atom(s), and most preferably tetrahydrofuranyl,<br>
tetrahydropyranyl, etc.<br>
Examples of the lower alkyl represented by R2 are the same<br>
as the said lower alkyl as the lower alkyl substituted by a lower<br>
alkoxy or a heterocyclic group represented by R1, and include<br>
preferably methyl, ethyl and isobutyl. The lower alkyl<br>
represented by R2 is preferably substituted by a phenyl group.<br>
Preferable examples of such phenyl-substituted lower alkyl<br>
group include benzyl, phenethyl, etc.<br>
Examples of the lower alkyl represented by R3 are the same<br>
as the said lower alkyl as the lower alkyl substituted by a<br>
lower alkoxy or a heterocyclic group represented by R1, and may<br>
include a cycloalkyl group. Such cycloalkyl group can be<br>
cyclopropane, cyclobutane, cyclopentane, cyclohexane, etc.,<br>
among which cyclopropane and cyclobutane are preferable.<br>
Examples of the halogen by which the above lower alkyl<br>
group may be substituted include fluorine, chlorine, bromine,<br>
etc., among which fluorine is preferable.<br>
Examples of the fused polycyclic hydrocarbon group<br>
include indanyl, indenyl, naphthyl, pentalenyl, azulenyl, etc. ,<br>
among which indanyl is preferable.<br>
In addition, the compounds of the present invention<br>
include a variety of solvates, polymorphs and pro-drugs.<br>
The compounds of the present invention can be prepared,<br>
for example, according to the following method.<br><br><br>
(wherein R is a protecting group, and other groups have the same<br>
meaning as defined above)<br>
Step a is a process which comprises adding a protecting<br>
group into an amino group of amino acids of the formula (III) ,<br>
converting the protected product into a mixed anhydride, and<br>
reducing the mixed anhydride with a reducing agent to yield a<br>
compound of the formula (V) (hereinafter referred to as compound<br>
(V)). The above-mentioned addition and deprotection<br>
procedures of the protecting group(s) can be carried out by the<br>
conventional method. Examples of such protecting groups used<br>
are formyl, optionally substituted C1-6 alkylcarbonyl (e.g.<br>
acetyl, propionyl, etc.), optionally substituted<br>
phenylcarbonyl, optionally substituted C1-6 alkyl-oxycarbonyl<br><br>
(e.g. methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl,<br>
etc.), optionally substituted phenyloxycarbonyl and<br>
optionally substituted C7-10 aralkyloxycarbonyl (e.g.<br>
phenyl-C1-4 alkyloxycarbonyl such as benzyloxycarbonyl, etc.) .<br>
As the substituent, halogen (e.g. fluorine, chlorine, bromine,<br>
iodine, etc. ) , nitro or the like is used, and the number of such<br>
substituents is approximately 1 to 3. Preferable substituent<br>
may be tert-butoxycarbonyl (Boc).<br>
Examples of the reducing agent used in the above reaction<br>
include lithium aluminum hydride, sodium borohydride, sodium<br>
bis(2-methoxyethoxy)aluminum hydride or the like, among which<br>
sodium borohydride is preferable. The reaction temperature is<br>
-40°C to 30°C, preferably -20°C to 0°C.<br>
The compound (V) may be prepared by adding an<br>
amino-protecting group to an amino alcohol of the formula (IV)<br>
in a similar manner (step a').<br>
Step b is a process of oxidizing a compound (V) with<br>
dimethyl sulfoxide (DMSO) in the presence of an activating<br>
reagent for DMSO to yield a compound of the formula (VI)<br>
(hereinafter referred to as compound (VI) ) . The DMSO oxidation<br>
can be carried out by the conventional method. For example,<br>
the compound (V) is dissolved in DMSO alone or in a mixture of<br>
DMSO and a solvent not inhibiting the oxidation (e.g.<br>
tetrahydrofuran, dichloromethane, chloroform, ethyl acetate,<br>
benzene, ether, etc.), and diisopropylethylamine is usually<br>
added thereto in an amount of approximately 1- to 10-fold in<br>
a molar ratio per one mole of compound (V) . The amount of DMSO<br>
used in the above reaction is approximately 1 to 20 mL to 1 g<br>
of compound (V). As the above activating reagent for DMSO,<br><br>
there are advantageously employed sulfur trioxide- pyridine<br>
complex, oxalyl chloride, dicyclohexylcarbodiimide, acetic<br>
anhydride or the like. Inter alia, sulfur trioxide-pyridine<br>
complex is preferably used.<br>
Step c is a process of preparing a compound of the formula<br>
(VII) (hereinafter referred to as compound (VII)) as a<br>
diastereomer mixture, which comprises treating a compound (VI)<br>
with sodium hydrogen sulfite, reacting the product with sodium<br>
cyanide to yield a cyanohydrin compound, hydrolyzing the<br>
cyanohydrin compound with an acid or alkali catalyst without<br>
purification to yield a diastereomer mixture of<br>
α-hydroxy-β-amino acid, and adding again the above<br>
amino-protecting group to the α-hydroxy-β-amino acid in a<br>
similar manner.<br>
This hydrolysis reaction is carried out by heating or by<br>
heating under reflux with an acid (e.g. hydrochloric acid,<br>
sulfuric acid, acetic acid, formic acid, etc. ) or an alkali (e.g .<br>
sodium hydroxide, potassium hydroxide, barium hydroxide, etc.) .<br>
The heating temperature is about 50°C to about 100°C. As the<br>
solvent, a mixture of water and an organic solvent (e.g. dioxane ,<br>
tetrahydrofuran, etc.) is preferably used.<br>
Step d is a process of condensing a compound (VII) with<br>
a variety of amines to yield a compound of the formula (VIII)<br>
(hereinafter referred to as VIII).<br>
As to an amine, a suitable amine can be appropriately<br>
selected depending on the objective compound. Examples of such<br>
amines include ethylamine, propylamine, cyclopropylamine,<br>
butylamine, cyclobutylamine, methoxyethylamine,<br>
2-phenoxyethylamine,	2-aminoindane,<br><br>
2,2,2-trifluoroethylamine or the like.<br>
It is preferable to carry out the above condensation in<br>
the presence of a dehydrative condensing agent such as<br>
1 - ethyl - 3 - (3 - dimethylaminopropyl) carbodiimide hydrochloride,<br>
N,N-dicyclohexylcarbodiimide, etc. Examples of the organic<br>
solvent used in the condensation reaction include<br>
N,N-dimethylformamide, DMSO, tetrahydrofuran,<br>
dichloromethane, methanol, ethanol, benzene, toluene, ethyl<br>
acetate, etc., and a mixture thereof, among which<br>
N,N-dimethylformamide is preferable. The reaction<br>
temperature is within the range of ice-cooling to room<br>
temperature.<br>
The step e is a process of deprotecting amino-protecting<br>
group(s) of a compound (VIII) under acidic condition with<br>
hydrochloric acid to yield an amine hydrochloride of the formula<br>
(IX) (hereinafter referred to as compound (IX)). Such<br>
deprotection of amino-protecting group(s) can be carried out<br>
by the conventional method. For example, the compound (VIII)<br>
is dissolved in an organic solvent which is commonly used, and<br>
then the solution is stirred in the presence of an acid to remove<br>
the amino-protecting group(s). Examples of the acid include<br>
hydrochloric acid, trifluoroacetic acid, p-toluenesulfonic<br>
acid or the like. Alternatively, commercially available<br>
HCl/ethyl acetate or HCl/dioxane may be used to remove<br>
amino-protecting group(s) . The reaction temperature is within<br>
the range of ice-cooling to room temperature.<br>
Step f is a process of condensing a compound of the formula<br>
(IX) with a compound of the formula (X) (hereinafter referred<br>
to as compound (X) ) in the presence of triethylamine to yield<br><br>
a compound of the formula (XI) (hereinafter referred to as<br>
compound (XI).<br>
The above compound (X) can be prepared according to the<br>
general reaction scheme given below.<br><br>
(wherein each symbol has the same meaning as defined above)<br>
An alcohol of the formula (XIII) (hereinafter referred<br>
to as alcohol (XIII)) is reacted with di(N-succinimidyl)<br>
carbonate to yield a mixed carbonic ester of the formula (XIV) ,<br>
which is then condensed with L-leucine ethyl ester<br>
hydrochloride in the presence of triethylamine to yield a<br>
compound of the formula (XV). Alkali saponification of the<br>
compound (XV) affords a compound of the formula (XVI)<br>
(hereinafter referred to as (XVI)). Alternatively, the<br>
compound (XVI) may be obtained by direct reaction between<br>
L-leucine and chloroformate. The compound (XVI) is reacted<br>
with hydroxysuccinimide (HOSu) to yield a succinimide ester of<br>
the formula (X) (hereinafter referred to as compound (X)).<br><br>
Step g is a process of oxidation of a compound. (XI) to<br>
produce a compound of the formula (XII) (hereinafter referred<br>
to as compound (XII). The oxidation reaction is carried out<br>
by per se conventional methods , including those classified into<br>
(i) chromium oxidation such as pyridinium dichromate (PDC)<br>
oxidation, pyridinium chlorochrornate (PCC) oxidation, Jones<br>
oxidation and Collins oxidation, and (ii) DMSO oxidation such<br>
as Swern oxidation, DMSO/sulfur trioxide-pyridine complex<br>
oxidation, DMSO/dicyclohexcylcarbodiimide oxidation,<br>
DMSO/oxalyl chloride oxidation, Dess-Martin oxidation using<br>
Dess-Martin , periodinane, hypohalogen acid oxidation and<br>
N-halogenocarboxylic amide oxidation, among which Dess-Martin<br>
oxidation is preferable. In carrying out Dess-Martin<br>
oxidation, the compound (XI) is dissolved in a commonly used<br>
organic solvent and Dess-Martin reagent is added thereto.<br>
Examples of the commonly used organic solvents include<br>
conventional solvents not adversely affecting the reaction or<br>
a mixture thereof, such as dichloromethane, N,N-<br>
dimethylformamide, DMSO, tetrahydrofuran, methanol, ethanol,<br>
benzene, toluene, ethyl acetate or the like, among which<br>
dichloromethane is preferable. The amount of the Dess-Martin<br>
reagent is approximately 1- to 20-fold mole equivalents,<br>
preferably 1- to 3-fold mole equivalents of the compound (XI).<br>
The reaction temperature is not particularly limited, and it<br>
is within the range of ice-cooling to room temperature. The<br>
compound (XII) thus obtained can be separated and purified by<br>
conventional methods including, for example, concentration,<br>
concentration in vacuo, solvent extraction, crystallization,<br>
recrystallization, solvent transfer, chromatography or the<br><br>
like.<br>
The each step as mentioned above is carried out in a<br>
commonly used solvent not adversely affecting the reaction, and<br>
a mixture thereof. Examples of such a solvent not adversely<br>
affecting the reaction include dichloromethane,<br>
N,N-dimethylformamide, DMSO, tetrahydrofuran, methanol,<br>
ethanol, benzene, toluene, ethyl acetate or the like.<br>
Specific examples of compounds (I) of the formula<br>
prepared according to the above method include<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(ethylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 1),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(ethylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid (3S)-tetrahydro-furan-3-yl<br>
ester(Compound 2),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(ethylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic<br>
acid tetrahydro-4H-pyran-4-yl ester (Compound 3),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 4),<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-<br>
dioxo-propyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
(3S)-tetrahydro-furan-3-yl ester (Compound 5),<br>
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-<br>
dioxo-propyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
tetrahydro-4H-pyran-4-yl ester (Compound 6),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br><br>
(propylamine)) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 7),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclobutylamino) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 8),<br>
((1S)-1-((((1S)-1-benzyl-3-butylamino-2,3-<br>
dioxo -propyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
2-methoxyethyl ester (Compound 9),<br>
((1S)-1-((((1S)-1-benzyl~2,3-dioxo-3-(2,2,2-<br>
trif luoroethylamino) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 10) ,<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(2-<br>
indanylamino) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 11) ,<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(2-<br>
methoxyethylamino) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 12) ,<br>
((1S)-1-((((1S)-2,3-Dioxo-3-ethylamino-1-<br>
(phenylethyl) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 13) ,<br>
((1S)-1-((((1S)-2,3-dioxo-3-ethylamino-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid (3S)-tetrahydro-furan-3-yl ester<br>
(Compound 14),<br>
((1S)-1-((((1S)-2,3-dioxo-3-cyclopropylamino-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 15) ,<br>
((1S)-1-((((1S)-2,3-dioxo-3-cyclopropylamino-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-<br><br>
methylbutyl)carbamic acid (3S)-tetrahydro-furan-3-yl ester<br>
(Compound 16),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbony1)-3-<br>
methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester<br>
(Compound 17),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 8-methoxy-3,6-dioxaoctyl ester<br>
(Compound 18),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl) carbamic acid 11-methoxy-3, 6, 9-trioxaundecanyl<br>
ester (Compound 19),<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 14-methoxy-3,6,9,12-<br>
tetraoxa-tetradecanyl ester (Compound 20),<br>
((1S)-1-((((1S)-2,3-dioxo-1-(2-methylpropyl)-3-(2-<br>
phenoxyethyl)aminopropyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester(Compound 21),<br>
((1S)-1-((((1S)-2.3-dioxo-1-(2-methylpropyl)-3-(2-<br>
phenoxyethyl)aminopropyl)amino)carbonyl)-3-<br>
methylbutyl) carbamic acid 5-methoxy-3-oxa-pentyl ester<br>
(Compound 22),<br>
((1S)-1-((((1RS)-3-amino-1-benzyl-2,3-dioxo-<br>
propyl)amino)carbonyl)-3-methylbutyl)carbamic	acid<br>
5-methoxy-3-oxa-pentyl ester (Compound 23),<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-<br><br>
dioxo-propyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-(pyridin-2-yl)ethyl ester (Compound 24),<br>
( (lS)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-(6-methylpyridin-2-yl)ethyl ester (Compound 25),<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-(5-ethylpyridin-2-yl)ethyl ester (Compound 26),<br>
((1S)-1-((((1S)-1-benzyl-3~(cyclopropylamino)-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-tert-butoxyethyl ester (Compound 27),<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-isopropoxyethyl ester (Compound 28) and the like, among which<br>
compounds 4, 17, 18, 19 and 24 are preferable.<br>
These compounds of the present invention have not yet been<br>
reported in literatures, and thus are novel. As shown in Test<br>
Examples which will be hereinafter described, the compounds of<br>
the present invention have an excellent calpain inhibitory<br>
activity. Accordingly, a medicament containing a compound of<br>
the present invention as active ingredient, optionally together<br>
with a combination of carriers which will be hereinafter<br>
described, is useful as a calpain inhibitor.<br>
The medicament containing a compound of the present<br>
invention is useful as a prophylactic or therapeutic agent for<br>
mammal (e.g. human, rat, mouse, rabbit, cattle, pig, dog, cat)<br>
diseases related to calpain such as ischemic disease,<br>
immunologic disease, multiple sclerosis, Alzheimer's disease,<br>
osteoporosis , diseases caused by brain tissue damage, cataract,<br><br>
glaucoma, retinochoroiditis disease (diabetic retinopathy,<br>
retinal vein occulusion, macular degeneration, retinitis<br>
pigmentosa, hypertensive retinopathy, retinal detachment,<br>
etc.), posterior eyeball complications due to photocoagulation<br>
(e.g. macular edema, retinal detachment, optic neuritis, visual<br>
field defect, light sense defect, dyschromatopsia, etc.), a<br>
disease involving neovascularization or the like.<br>
In addition, a compound of the present invention has<br>
excellent tissue transport and high absorbability as well as<br>
high safety with very low toxicity.<br>
The medicament containing a compound of the present<br>
invention can be administered systemically or locally.<br>
Besides oral administration. The systemic administration<br>
includes, besides oral administration, parenteral<br>
administration route such as intravenous injection,<br>
subcutaneous injection, intramuscular injection or the like.<br>
In case of the local administration, the medicament is applied<br>
via transdermal, mucous membrane, nasal or ophthalmic route,<br>
etc.<br>
The dosage form of the medicament containing a compound<br>
of the present invention includes solid preparations (e.g.<br>
powders, granules, tablets, capsules, suppositories, etc.) and<br>
liquid preparations (e.g. syrups, injections, eyedrops, nasal<br>
drops, etc.). In the production of granules or tablets, any<br>
dosage form can be prepared with the use of pharmaceutically<br>
acceptable additives such as excipients (e.g. lactose, sucrose,<br>
glucose, starch, crystalline cellulose, etc.), lubricants (e.g.<br>
magnesium stearate, talc, stearic acid, calcium stearate),<br>
disintegrators (e.g. starch, carmellose sodium, calcium<br><br>
carbonate, etc.), or binders (e.g. starch paste,<br>
hydroxypropylcellulose solution, carmellose solution, gum<br>
arable solution, gelatin solution, sodium alginate solution,<br>
etc.). Further, granules and tablets may be coated with a<br>
coating agent (e.g. gelatin, white sugar, gum arable, carnauba<br>
wax, etc.) or an enteric coating agent (e.g. cellulose acetate<br>
phthalate, methacrylic copolymer, hydroxypropylcellulose<br>
phthalate, carboxymethylethyl cellulose, etc.).<br>
In the production of capsules, conventional excipients<br>
such as magnesium stearate, calcium stearate, talc and light<br>
silicic acid, anhydride, etc., for improving flowability and<br>
lubricity; crystalline cellulose and lactose for increasing<br>
flowability under pressure; and the above-mentioned<br>
disintegrators are appropriately selected, and mixed or<br>
granulated homogenously with the compound of the present<br>
invention, then filled in capsules. Alternatively, the<br>
granulated products may be coated with a suitable coating agent,<br>
then filled in capsules, or may be encapsulated with an<br>
appropriate capsule base (e.g. glycerin) having increased<br>
plasticity endowed with addition of glycerin or sorbitol. If<br>
required, coloring agents, preservatives (e.g. sulfur dioxide,<br>
parabens such as methyl p-oxybenzoate, ethyl p-oxybenzoate and<br>
propyl p-oxybenzoate), etc. may be added to the capsule<br>
preparations. Enteric coated capsules, gastric resistant<br>
capsules or release controlled capsules may be formulated in<br>
addition to conventional capsule preparations. In the case of<br>
enteric coated capsule preparations, they are prepared by<br>
filling regular capsules with the compound of the present<br>
invention which is coated with an enteric coating agent or to<br><br>
which said appropriate excipient is added, or alternatively,<br>
they are prepared by filling capsules coated with an enteric<br>
coating agent or capsules made from an enteric polymer as a base<br>
material with the compound of the present invention optionally<br>
together with said appropriate excipient. In the production<br>
of suppositories, an appropriate suppository base (e.g. cacao<br>
butter, macrogol, etc.) can be used.<br>
In the production of syrups, stabilizers (e.g. sodium<br>
edetate, etc.), suspending agents (e.g. gum arablc, carmellose,<br>
etc.), corrigents (e.g. simple syrup, glucose, etc.), perfumes<br>
or the like can be appropriately used.<br>
Injections, eye-drops or nasal drops of the present<br>
invention can be produced by dissolving or dispersing the<br>
compound of the present invention in a solution containing an<br>
appropriate isotonic (e.g. sodium chloride, potassium chloride,<br>
glycerin, mannitol, sorbitol, boric . acid, borax, glucose,<br>
propylene glycol, etc.), buffer (e.g. phosphate buffer, acetate<br>
buffer, borate buffer, carbonate buffer, citrate buffer, Tris<br>
buffer, glutamate buffer, e-aminocapronate buffer, etc.),<br>
preservative (e.g. methyl p-oxybenzoate, ethyl p-oxybenzoate,<br>
propyl p-oxybenzoate, chlorobutanol, benzyl alcohol,<br>
benzalkonium chloride, sodium dehydroacetate, sodium edetate,<br>
boric acid, borax, etc.), thickener (e.g.<br>
hydroxyethylcellulose, hydroxypropylcellulose, polyvinyl<br>
alcohol, polyethylene glycol, etc.), stabilizer (e.g. sodium<br>
hydrogensulfite, sodium thiosulfate, sodium edetate, sodium<br>
citrate, ascorbic acid, dibutylhydroxytoluene, etc.), pH<br>
controlling agent (e.g. hydrochloric acid, sodium hydroxide,<br>
phosphoric acid, acetic acid, etc.) or the like.<br><br>
Although the amount of the additive to the above injection,<br>
eye drop or nasal drop depends on the kind and the purpose of<br>
the additive to be added, it is sufficient to add the amount<br>
of the additive that can achieve the purpose. Usually, an<br>
isotonic is preferably added in an amount of about 0.5 to about<br>
5.0 w/v % so that the osmotic pressure reaches about 229 mOsm<br>
to about 343 mOsm. Preferred concentrations of buffer,<br>
thickner and stabilizer to be added are about 0.01 to about 2.0<br>
w/v %, about 0.01 to about 1.0 w/v % and about 0.001 to about<br>
1.0 w/v %, respectively. A pH controlling agent is<br>
appropriately added to adjust the pH usually to about 3 to about<br>
9, preferably about 4 to about 8.<br>
The dose of the compound of the present invention depends<br>
on the target diseases, symptom of the disease, subject to be<br>
administered, administration route or the like. For example,<br>
in the case of oral administration to an adult patient, the dose<br>
is about 1 to about 200 mg, preferably about 10 to about 100<br>
mg for a single dose, once to several times a day. In the case<br>
of injection to an adult patient, the dose is about 0.1 to about<br>
50 mg, preferably about 1 to about 30 mg, once a day. For topical<br>
administration to the eyes, it is preferable to administer eye<br>
drops containing usually about 0.001 to about 1.0 w/v %,<br>
preferably about 0.01 to about 0.5 w/v %, in an amount of about<br>
20 to about 50 µL per dose, several times a day.<br>
Examples<br>
The present invention will be explained in detail by way<br>
of Reference Examples, Examples, Test Examples and Formulation<br>
Examples, however, the invention is not restricted thereto.<br><br>
In the analytical data of the compounds described in the<br>
Examples, melting points were determined on a Yanaco micro<br>
melting point apparatus without correction. 1H-NMR spectra<br>
were recorded on a Varian Gemini-2000 spectrometer. Chemical<br>
shifts are reported in parts per million, and coupling constants<br>
(J) are reported in hertz. Matrix-assisted laser desorption<br>
ionization time-of-flight mass spectra (MALDI-TOF-MS) were<br>
obtained on a Perseptive Voyager DE mass spectrometer, and the<br>
mass numbers were corrected with an internal standard<br>
(a-cyano-4-hydroxycinnamic acid) and displayed accurately.<br>
Reference Example 1<br>
N- ((2-Methoxyethoxy)carbonyl)-1-leucine N-hydroxy-<br>
succinimide ester<br>
(1) To a solution of L-leucine (25 g, 0.19 mol) was<br>
dissolved in 2M NaOH (0.12 L) was slowly added 2-methoxyethyl<br>
chloroformate (30 g, 0.22 mol) and 1M NaOH at the same time<br>
under the ice-cooled condition. The mixture was stirred at room<br>
temperature for 18 hours, diluted into water (600 mL) and washed<br>
with ethyl ether (2 x 200 mL) . The aqueous phase was cooled<br>
in an ice bath and acidified to pH 3 with 6M HC1. This mixture<br>
was extracted with ethyl acetate (EtOAc) (5 x 150 mL) . The<br>
organic phase was dried over anhydrous MgSO4 and filtered, and<br>
the filtrate was concentrated in vacuo to yield N-((2-<br>
methoxyethoxy)carbonyl)-1-leucine (41 g, 92%) as a colorless<br>
oil.<br>
(2) N-((2-Methoxyethoxy)carbonyl)-1-leucine (20 g, 86<br>
mmol) and N-hydroxysuccinimide (13 g, 0.11 mmol) were dissolved<br>
in THF (200 mL), and a suspension of 1-ehtyl-3-(3-<br><br>
dimethylaminopropyl)carbodiimide hydrochloride (21 g, 0.11<br>
mol) in CH2Cl2 (200 mL) was added thereto. The mixture was<br>
stirred at room temperature for 18 hours, and concentrated in<br>
vacuo. The residue was dissolved in EtOAc (300 mL), and the<br>
solution was washed with 1M HCl (150 mL), saturated aqueous<br>
NaHCO3 (150 mL) and saturated aqueous NaCl (150 mL) , dried over<br>
anhydrous MgSO4, and concentrated in vacuo to give the title<br>
compound (27 g, 95%) as a colorless oil.<br>
1H-NMR (300MHz,DMSO-d6) δ 0.89 (d,3H,J=6.6),0.93(d,3H,J= 6.6) ,<br>
1.57-1.84(m,3H),2.81(s,4H),3.26(s,3H),3.51(t,2H,J=4.7),<br>
4.10(t,2H,J=4.7),4.40(m,lH),8.04(d,lH,J=8.1).<br>
Reference Example 2<br>
(1)N-(((3S)-Tetrahydrofuran-3-yloxy)carbonyl)-1-<br>
leucine N-hydroxysuccinimide ester<br>
To a stirred solution of (S)-3-hydroxytetrahydrofuran<br>
(1.0 g, 11 mmol) in acetonitrile (50 mL) at room temperature<br>
were added N,N'-disuccinimidyl carbonate (4.3 g, 17 mmol) and<br>
triethylamine (4.4 g, 17 mmol, 4.8 mL) . The resulting mixture<br>
was stirred at room temperature for 18 hours, and concentrated<br>
in vacuo .' The residue was diluted with saturated aqueous NaHCO3<br>
(100 mL) and extracted with EtOAc (200 mL) . The combined<br>
organic extracts were washed with saturated aqueous NaCl (100<br>
mL), dried over anhydrous MgSO4, and concentrated in vacuo to<br>
give N-succinimidyl (3S)-3-tetrahydrofranyl carbonate (2.6 g)<br>
as a brown oil in a quantitative yield.<br>
( 2) To a solution of L-leucine ethyl ester hydrochloride<br>
(2.7 g, 14 mmol) and triethylamine (2.9 g, 2 8 mmol) in<br>
dichloromethane (50 mL) was added a solution of N-succinimidyl<br><br>
(3S)-3-tetrahydrofurnaylcarbonate (2.6 g, 11 mmol) in<br>
dichloromethane (20 mL), and the mixture was stirred at room<br>
temperature for 18 hours, then concentrated in vacuo. The<br>
residue was dissolved in ethyl acetate (200 mL), and the<br>
solution was washed successively with 1M hydrochloric acid,<br>
saturated aqueous NaHCO3 and saturated aqueous NaCl, dried over<br>
anhydrous magnesium sulfate, and concentrated in vacuo. The<br>
residue was washed with hexane to give<br>
N-(((3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine ethyl<br>
ester (3.1 g, 98%) as a white solid.<br>
(3) To a solution of N-(((3S)-tetrahydrofuran-3-<br>
yloxy)carbonyl)-1-leucine ethyl ester (2.9 g, 11 mmol) in EtOH<br>
(100 mL) was added 1M NaOH (33 mL) . The mixture was stirred<br>
under ice-cooling condition for 3 hours, and then adjusted to<br>
pH 3 by the addition of HCl thereto. The solution was<br>
concentrated in vacuo, and the residue was extracted with ethyl<br>
acetate (100mL) . Then, the organic layer was separated, washed<br>
with 1M HCl and saturated aqueous NaCl, dried over anhydrous<br>
MgSO4 and concentrated in vacuo. The residue was crystallized<br>
from ethyl acetate and hexane to give<br>
N-(((3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine (2.6 g,<br>
85%) as colorless crystals.<br>
M.p. 94.9-96.0°C<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using<br>
N-(((3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine in<br>
place of N-((2-methoxyethoxy)carbonyl)-1-leucine, there was<br>
obtained the title compound as a colorless oil.<br>
1H-NMR(300MHz,DMSO-d6) δ 0.89 (d,3H,J=6.0),0.92(d, 3H, J=6.3),<br><br>
1.55-1.82(m,3H),1.88 (m, 1H),2.12(m, 1H),2.81(s,4H), 3.64-3.84<br>
(m,4H),4.39(m,lH),5.l5(m,lH),8.04(d,1H,J=7.8).<br>
Reference Example 3<br>
N- ((Tetrahydro-4H-pyran-4-yloxy)carbonyl) -1-leucine<br>
N-hydroxysuccinimide ester<br>
(1) N-Succinimidyl tetrahydro-4H-pyran-4-ylcarbonate<br>
was obtained as a brown oil in a manner similar to Reference<br>
Example 2(1), using 4-hydroxytetrahydro-4H-pyran in place of<br>
(S)-3-hydroxytetrahydrofuran, there was obtained<br>
N-succinimidyl tetrahydro-4H-pyran-4-ylcarbonate as a brown<br>
oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using N-succinimidyl tetrahydro-<br>
4H-pyran-4-ylcarbonate in place of N-succinimidyl<br>
(3S)-3-tetrahydrofuranyl carbonate, there was obtained<br>
N-( (tetrahydro-4H-pyran-4-yloxy)carbonyl)-1-leucine ethyl<br>
ester as a colorless solid.<br>
(3)	Working up in a manner similar to Reference Example<br>
2(3) and using N-(5-methoxy-3-oxaopentyloxy)carbonyl)-1-<br>
leucine ethyl ester in place of N-(((3S)-tetrahydrofuran-<br>
3-yloxy)carbonyl) -1-leucine ethyl ester, there was obtained N-<br>
((tetrahydro-4H-pyran-4-yloxy)carbonyl)-1-leucine as a<br>
colorless solid.<br>
(4)	Using N-((tetrahydro-4H-pyran-4-yloxy)carbonyl)-<br>
L-leucine) in place of N-(2-(methoxyethoxy)carbonyl)-<br>
L-leucine, a similar reaction to Reference Example 1(2) gave<br>
the title compound as a colorless oil.<br>
1H-NMR(300MHz,DMSO-d6) δ 0.89(d,3H,J=6.0),0.92(d,3H,J= 6.3),<br><br>
1.43-1.93(m,7H),2.80(s,4H),3.42(m,2H),3.78-3.82(m, 2H) , 4.39<br>
(m,1H),4.72(m,1H),7.94(d,1H,J=7.8).<br>
Reference Example 4<br>
N-((5-Methoxy-3-oxapentyloxy)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using diethylene glycol monomethyl<br>
ether in place of (S)-3-hydroxytetrahydrofuran, there was<br>
obtained 5-methoxy-3-oxapentyl N-succinimidyl carbonate as a<br>
colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using 5-methoxy-3-oxapentyl<br>
N-succinimidyl carbonate in place of N-succinimidyl<br>
(3S)-3-tetrahydrofuranyl carbonate, there was obtained<br>
N- ((5-methoxy-3-oxapentyloxy)carbonyl) -1-leucine ethyl ester<br>
as a colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N- ((5-methoxy-3-<br>
oxapentyloxy)carbonyl)-1-leucine ethyl ester in place of<br>
N- ((3S)-tetrahydrof uran-3-yloxycarbonyl)-1-leucine ethyl<br>
ester, there was obtained N-((5-methoxy~3-<br>
oxapentyloxy)carbonyl)-1-leucine as a colorless oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N- ((5-methoxy-3-<br>
oxapentyloxy)carbonyl)-1-leucine in place of N-((2-<br>
methoxyethoxy)carbonyl-1-leucine, there was obtained the<br>
title compound as a colorless oil.<br>
1H-NMR(300MHz,DMSO-d6) δ 0.90(dd,6H,J=9.5,6.5),1.56-1.80(m.<br><br>
3H),2.80(s,4H),3.24(s,3H),3.41-3.46(m,2H),3.50-3.54(m,2H),<br>
3.56-3.60(m,2H),4.08-4.11(m,2H),4.39(m,1H),8.05(d,1H,J=7.8).<br>
Reference Example 5<br>
N-((8-Methoxy-3,6-dioxaoctyloxy)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using triethylene glycol monomethyl<br>
ether in place of (S)-3-hydroxytetrahydrofuran, there was<br>
obtained 8-methoxy-3,6-dioxaoctyl N-succinimidyl carbonate as<br>
a colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using 8-methoxy-3,6-dioxaoctyl<br>
N- succinimidyl carbonate in place of N-succinimidyl<br>
(3S)-3-tetrahydrofuranyl carbonate, there was obtained<br>
N-((8-methoxy-3,6-dioxaoctyloxy)carbonyl)-1-leucine ethyl<br>
ester as a colorless oil.<br>
(3)	Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N- (8-methoxy-3,6-<br>
dioxaoctyloxy)carbonyl)-1-leucine ethyl ester in place of<br>
N-(((3S)-tetrahydrofuran-3-yloxy)carbonyl-1-leucine ethyl<br>
ester, there was obtained N-((8-methoxy-3,6-<br>
dioxaoctyloxy)carbonyl)-1-leucine as a colorless oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N-((8-methoxy-3,6-<br>
dioxaoctyloxy)carbonyl)-1-leucine in place of N-((2-<br>
methoxyethoxy)carbonyl)-1-leucine, there was obtained the<br>
title compound as a colorless oil.<br>
1H-NMR(300MHz,DMSO-d6) δ 0.89(d,3H,J=6.3),0.92(d,3H,J=6.3),<br><br>
1.56-1.82(m,3H),2.81(s,4H),3.24(s,3H),3.43(m,2H),3.52(m,<br>
6H),3.59(m,2H),4.10(m,2H),4.40(m,1H),8.06(d,1H,J=7.8).<br>
Reference Example 6<br>
N-((11-Methoxy-3,6,9-trioxaundecanyloxy)carbonyl)-1-<br>
leucine N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using tetraethylene glycol<br>
monomethyl ether in place of (S)-3-hydroxytetrahydrofuran,<br>
there was obtained 111-methoxy-3, 6,9-trioxaundecanyl<br>
N-succinimidyl carbonate as a colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using<br>
111-methoxy-3, 6 , 9-trioxaundecanyl N-succinimidyl carbonate in<br>
place of N-succinimidyl (3S)-3-tetrahydrofurahyl carbonate,<br>
there was obtained N-((111-methoxy-3,6,9-<br>
trioxaundecanyloxy)carbonyl-1-leucine ethyl ester as a<br>
colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N- ((111-methoxy-3,6,9-<br>
trioxa-undecanyloxy)carbonyl-1-leucine ethyl ester in place<br>
of N- (((3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine<br>
ethyl ester, there was obtained N- ((111-methoxy-3,6,9-<br>
trioxa-undecanyloxy)carbonyl)-1-leucine as a colorless oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N- ((111-methoxy-3,6,9-<br>
trioxaundecanyloxy)carbonyl)-1-leucine in place of N-((2-<br>
methoxyethoxy)carbonyl)-1-leucine, there was obtained the<br>
title compound as a colorless oil.<br><br>
1H-NMR(300 MHz,DMSO-d6) δ 0. 91 (dd, 6H, J=9 . 3 , 6 . 3) , 1. 56-1. 77(m,<br>
3H),2.81(s,4H),3.24(s,3H),3.41-3.44(m,2H),3.49-3.52(m,10H) ,<br>
3.59(t,2H,J=4.7),4 . 08-4.11(m,2H),4.38(m,1H),8.06(d,1H,J=7 . 8<br>
).<br>
Reference Example 7<br>
N-((14-Methoxy-3,6,9,12-tetraoxatetradecanyloxy)carbonyl)-<br>
L-leucine N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using pentaethylene glycol<br>
monomethyl ether in place of (S)-3-hydroxytetrahydrofuran,<br>
there was obtained 14-methoxy-3 , 6 , 9 ,12-tetraoxa-tetradecanyl<br>
N-succinimidyl carbonate as a colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using<br>
14-methoxy-3 , 6,9,12-tetraoxa-tetradecanyl AT-succinimidyl<br>
carbonate in place of N-succinimidyl (3S)-3-tetrahydrofuranyl<br>
carbonate, there was obtained N-((14-methoxy-3,6,9,12-<br>
tetraoxa-tetradecanyloxy)carbonyl)-1-leucine ethyl ester as a<br>
colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N- ((14-methoxy-3,6,9,12-<br>
tetraoxa-tetradecanyloxy)carbonyl-1-leucine ethyl ester in<br>
place of N-( (3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine<br>
ethyl ester, there was obtained N- ((14-methoxy-3,6,9,12-<br>
tetraoxa-tetradecanyloxy)carbonyl)-1-leucine as a colorless<br>
oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N- ((14-methoxy-3,6,9,12-<br><br>
tetraoxa-tetradecanyloxy)carbonyl L-leucine in place of<br>
N-((2-methoxyethoxy)carbonyl) -1- leucine, there was obtained<br>
the title compound as a colorless oil.<br>
1H-NMR(300MHz,DMSO-d6) δ 0.89(d,3H,J=6.6),0.92(d,3H,J=6.3) ,<br>
1.57-1.82(m,3H),2.81(s.4H),3.24(s,3H),3.43(m,2H),3.51(m,<br>
14H),3.59(m,2H),4.10(m,2H),4.40(m,1H),8.05(d,1H,J=7.8) .<br>
Reference Example 8<br>
(3S) -3-Amino-N-ethyl-2-hydroxy-4-phenylbutanamide<br>
hydrochloride<br>
(1) To a solution of L-phenylalaninol (50 g, 66 mmol)<br>
in tetrahydrofuran (1.3 L) and water (630 mL) , a solution of<br>
di-t-butyl dicaxbonate (140 g, 0.67 mol) in tetrahydrofuran<br>
(500 mL) and 1M NaOH (660 mL) were added slowly at the same time<br>
under ice-cooled condition. The mixture was stirred at room<br>
temperature for 18 hours, concentrated in vacuo, and diluted<br>
with ethyl acetate (EtOAc) (1 L) . The solution was washed with<br>
1M HCl, saturated aq. NaHCO3 and saturated aq. NaCl, dried over<br>
anhydrous MgSO4, and concentrated in vacuo. The resulting<br>
white solid was recrystalized from ethyl acetate/hexane (1:10).<br>
The crystal was filtered off to give N- (tert-butoxycarbonyl) -<br>
L-phenylalaninol (70 g, 84%) as colorless crystals.<br>
(2) N-(tert-Butoxycarbonyl) -1-phenylalaninol (69 g,<br>
0.28 mol) was dissolved in DMSO (280 mL) and CH2Cl2 (140 mL),<br>
and the solution was in an ice-bath. N,N-<br>
diisopropylethylamine (106 g, 0.82 mol) and a suspension of<br>
purified sulfur trioxide pyridine complex (130 g, 0.82 mol) in<br>
DMSO (100 mL) were added thereto. The mixture was stirred for<br>
1 hour under the same condition. The reaction mixture was<br><br>
diluted with EtOAc (1.5 L) , and the solution was washed with<br>
1M HCl, saturated aqueous NaHCO3 and saturated aqueous NaCl,<br>
dried over anhydrous MgSO4, and concentrated in vacuo. The<br>
residue was crystallized from a mixture of hexane and EtOAc to<br>
give N- (tert-butoxycarbonyl) - L-phenylalaninal (53 g, 77%) as<br>
colorless crystals.<br>
(3) N- (tert-Butoxycarbonyl) -1-phenylalaninal (17 g, 67<br>
mmol) was dissolved in MeOH (100 mL) and chilled to 5 °C. Sodium<br>
bisulfite (7.0 g, 67 mmol) was dissolved in water (150 mL) and<br>
chilled to 5 °C. The solution was added to the aldehyde solution,<br>
and the mixture was stirred at 5°C for 18 hours. NaCN (4.0 g,<br>
81 mmol) was dissolved in water (100 mL) and added with EtOAc<br>
(300 mL) to the above mixture. The reaction solution was<br>
stirred at room temperature for 5 hours. The organic layer was<br>
collected, dried over anhydrous MgSO4, and concentrated in<br>
vacuo to yield the cyanohydrin as a colorless oil. The<br>
cyanohydrin was dissolved in 1,4-dioxane (250 mL) and<br>
concentrated HCl (250 mL) , and 10 mL of anisole was added. The<br>
solution was gently refluxed for 18 hours, allowed to cool to<br>
room temperature and then concentrated in vacuo to give a brown<br>
semi-solid. The residue was dissolved in water (100 mL) and<br>
washed with ethyl ether (3 x 50 mL) . The aqueous phase was then<br>
placed on a Dowex 50X8- column (100-200 mesh, H+ form; 25 x 1.8<br>
cm). The column was washed with water until the pH 5.5, and<br>
eluted with 2M ammonium hydroxide (ca. 1.5 L) . The eluent was<br>
concentrated in vacuo to yield (3S)-3-amino-2-hydroxy-<br>
4-phenylbutanoic acid (12 g, 88%) as a white solid.<br>
(4) (3S) -3-Amino-2-hydroxy—4-phenylbutyric acid (11 g,<br>
56.34 mmol) was dissolved in 1M NaOH (70 mL), and to this<br><br>
solution was added a solution of di-t-butyl dicarbonate (12 g,<br>
57 mmol) in dioxane (70 mL) . The mixture was stirred at room<br>
temperature for 18 hours while the pH was maintained between<br>
10 and 11 with 1M NaOH. The mixture was diluted with water (600<br>
mL) , and washed with diethyl ether (2 x 200 mL) . The aqueous<br>
phase was chilled in an ice bath and acidified to pH 2 with 1M<br>
HCl. This mixture was extracted with ethyl ether (3 x 250 mL) .<br>
The organic phase was dried over anhydrous MgSO4 and<br>
concentrated in vacuo to yield (3S)-3-(tert-<br>
butoxycarbonylamino) -2-hydroxy-4- phenylbutanoic acid (12 g,<br>
72%) as a mixture of diastereomer which was a colorless solid.<br>
(5) (3S)-3-(tert-Butoxycarbonylamino)-2-hydroxy-4-<br>
phenylbutanoic acid ( 6 . 3 g, 21 mmol) and 1-hydroxybenzotriazole<br>
(HOBt) (3.0 g, 22. 4 mmol) were dissolved in DMF (45mL) and cooled<br>
in an ice bath. 1-Ethyl-3-(S-dimethylaminopropyl)carbodi-<br>
imide hydrochloride (EDC) (4.6 g, 24 mmol) was added, followed<br>
by aqueous ethylamine solution (3.0 mL). The solution was<br>
stirred for 18 hours. The solution was diluted into EtOAc (200<br>
mL) and washed with 1M HCl, saturated aqueous NaHCO3, and<br>
saturated aqueous NaCl. The organic layer was dried over<br>
anhydrous MgSO4 and concentrated in vacuo to yield<br>
((1S)-1-benzyl-3-ethylamino-2-hydroxy-3-oxo-<br>
propyl)carbamic acid 1,1- dimethylethyl ester (5.8 g, 84%) as<br>
a white solid.<br>
(6)((1S)-1-Benzyl-3-ethylamino-2-hydroxy-3-<br>
oxopropyl)carbamic acid 1,1-dimethylethyl ester (5.5 g, 17<br>
mmol) was dissolved in 4N HCl/dioxane (65 mL) and was stirred<br>
for 3 hours at room temperature. The solution was concentrated<br>
in vacuo to yield the title compound as a white solid (4.4 g)<br><br>
in a quantitative yield.<br>
M.p. 162.8-163.3°C.<br>
(Major)1H-NMR(300MHz,DMSO-d6) δ 1.02(t,3H,J=7.2),2.93(m,2H),<br>
3.05-3.20(m,2H),3.60(m,1H),3.88 (m,1H),6.75 (d,1H,3=6.0),<br>
7.19-7.37(m,5H),8.08(m,1H),8.17(br s,3H).<br>
(Minor ) 1H-NMR(300MHz ,DMSO-d6) δ 0 . 97 (t, 3H, J=7 . 4) , 2 . 80(d, 2H, J<br>
=6.9),3.00(m,2H),3.69(m,1H),4.26(m,1H).6.53(d,1H,J=5.4),<br>
7.19-7.37(m,5H),8.03(t,1H,J=5.7),8.17(br s,3H).<br>
Reference Example 9<br>
(3S)-3-Amino-N-cyclopropyl-2-hydroxy-4-phenylbutanamide<br>
hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using cyclopropylamine in place of<br>
aqueous ethylamine, there was obtained ((1S)-1-benzyl-3-<br>
cyclopropylamino-2-hydroxy-3-oxopropyl)carbamic acid<br>
1,1-dimethylethyl ester as a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-1-benzyl-3-<br>
cyclopropylamino-2-hydroxy-3-oxopropyl)carbamic acid<br>
1,1-dimethyl ester in place of ((1S)-1-benzyl-3-<br>
ethylamino-2-hydroxy-3-oxopropyl)carbamic acid 1,1- dimethyl<br>
ethyl ester, there was obtained the title compound as a white<br>
solid.<br>
M.p. 162.9-163.3°C<br>
1H-NMR(300MHz ,DMSO-d6) δ 0.44(m,2H),0.57(m,2H),2.50(m,0.5H),<br>
2.65(m,0.5H),2.82(d,1H,J=6.9),2.94(m,1H),3.60(m,0.5H),3.70<br>
(m,0.5H),3.87(m,0.5H),4.26(d,0.5H,J=2.4),6.45(br s,0.5H),<br>
6.69(br s,0.5H),7.23-7.35(m,5H),7.99(d,0.5H,J=4.2),8.08(br<br><br>
s,1.5H),8.09(d,0.5H,J=4.5),8.23(br s,1.5H).<br>
Reference Example 10<br>
(3S)-3-Amino-2-hydroxy-4-phenyl-W-propylbutanamide<br>
hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using propylamine in place of aqueous<br>
ethylamine,	there	was	obtained<br>
((1S)-1-benzyl-2-hydroxy-3-oxo-3-<br>
(propylamino)propyl)carbamic acid 1,1-dimethylethyl ester as<br>
a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-1-benzyl-2-hydroxy-<br>
3-OXO-3-(propylamino)propyl)carbamic acid 1,1-dimethylethyl<br>
ester in place of ((1S)-1-benzyl-3-ethylamino-2-hydroxy-3-<br>
oxopropyl)carbamic acid 1,1-dimethylethyl ester, there was<br>
obtained the title compound as a white solid.<br>
M.p. 127.8-129.5°C<br>
1H-NMR(300MHz ,DMSO-d6) δ 0.82(m,3H) , 1. 35-1. 47(m, 2H) ,2.82 (m,<br>
0.5H),2.95(m,3H),3.09(m,0.5H),3.58(m,0.5H),3.70(m,0.5H),<br>
3.92(m,0.'5H),4.31(m,0.5H) , 6 . 55 (d, 0 . 5H, J=4 .8) , 6 . 77 (d, 0 . 5H,<br>
J=6.6),7.21-7.36(m,5H),7.98-8.15(m,2.5H),8.24(br s,1.5H).<br>
Reference Example 11<br>
(3S) -3- Amino-AT-cyclobutyl- 2 -hydroxy- 4 -phenylbutanamide<br>
hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using cyclobutylamine in place of<br>
aqueous ethylamine, there was obtained ((1S)-1-benzyl-3-<br><br>
cyclobutylamino - 2 -hydroxy- 3 - oxopropyl) carbamic acid 1,1-<br>
dimethylethyl ester as a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-1-benzyl-3-<br>
cyclobu tylamino - 2 -hydroxy- 3 - oxopropyl) carbamic acid<br>
1,1-dimethylethy1 ester in place of ((1S)-1-benzyl-3-<br>
ethylamino-2-hydroxy-3-oxopropyl) carbamic acid 1,1-<br>
dimethylethyl ester, there was obtained the title compound as<br>
a white solid.<br>
M.p.l62.5-163°C.<br>
1H-NMR(300 MHz,DMSO-d6) δ 1.59(m,2H),1.88-2.18(m,4H),2.80(d,<br>
1H,J=6.6),2.91(m,1H),3.58(m,0.5H),3.69(m,0.5H),3.87(m,<br>
0.5H),4.08(m,0.5H),4.16-4.24(m,1H),6.50(d,0.5H,J=5.4),<br>
6.72(d,0.5H,J=6.0),7.21-7.33(m,5H),8.05(br s,1.5H),8.19(d,<br>
0.5H,J=7.8),8.20(br s,1.5H),8.29(d,0.5H,J=8.1).<br>
Reference Example 12<br>
(3S)-3-Amino-N-butyl-2-hydroxy-4-phenyl-butanamide<br>
hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using butylamine in place of aqueous<br>
ethylamine, there was obtained ((1S)-1-benzyl-3-butylamino-<br>
2-hydroxy-3-oxopropyl)carbamic acid 1,1-dimethylethy1 ester<br>
as a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-1-benzyl-3-butylamino-<br>
2-hydroxy-3-oxopropyl)carbamic acid 1,1-dimethylethyl ester<br>
in place of ((1S)-1-benzyl-3-ethylamino-2-hydroxy-3-<br>
oxopropyl)carbamic acid 1,1-dimethylethyl ester, there was<br><br>
obtained the title compound as a white solid.<br>
M.p. 141.0-141.4°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0 .86 (m, 3H) , 1.16-1. 47(m, 4H) , 2 . 80 (m,<br>
0.5H),2.99(m,3H).3.13(m,0.5H),3.57(m,0.5H),3.70 (m,0.5H),<br>
3.92(m,0.5H),4.30(m,0.5H),6.53(br s,0.5H),6.77(d,0.5H,J=<br>
6.6),7.19-7.39 (m,5H),7.97-8.15(m,2.5H),8.22(s,1.5H).<br>
Reference Example 13<br>
(3S)-3-Amino-2-hydroxy-4-phenyl-N~ (2,2,2-<br>
trifluoroethyl)butanamide hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using 2 , 2 , 2-trif luoroethylamine in<br>
place of aqueous ethylamine, there was obtained ((1S)-1-<br>
benzyl-2-hydroxy-3-oxo-3-(2,2,2-<br>
trifluoroethylamino)propyl)carbamic acid 1,1-dimethylethy1<br>
ester as a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using<br>
((1S)-1-benzyl-2-hydroxy-3-oxo-3-(2,2,2-<br>
trifluoroethylamino)propyl)carbamic acid 1,1-dimethylethyl<br>
ester in place of (((1S)-1-benzyl-3-ethylamino-2-hydroxy-<br>
3-oxopropyl)carbamic acid 1,1-dimethylethyl ester, there was<br>
obtained	(3S)-3-amino-2-hydroxy-4-phenyl-N-(2,2,2-<br>
trifluoroethyl)butanamide hydrochloride as a white solid.<br>
M.p. 103.0-108.5°C<br>
1H-NMRt300MHz,DMSO-d6) δ 2.71-2.85(m,1H),2.88-2.97(m,1H),<br>
3.60-3.82(m,2.5H),3.91-4.05(m,1H),4.45(m,0.5H),6.75(d,0.5H,<br>
J=5.7),6.98(d,0.5H,J=6.3),7.20-7.35(m, 5H),8.12 (brs,1.5H),<br>
8.25(br s,1.5H),8.70(m,1H).<br><br>
Reference Example 14<br>
(3 S) - 3 - Amino - 2 - hy dr oxy -N- (2 -indany 1) - 4 - phenylbutanamide<br>
hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using 2-aminoindane in place of<br>
aqueous ethylamine, there was obtained ((1S)-1-benzyl-3-<br>
(2-indanylamino)-2-hydroxy-3-oxo-propyl)carbamic acid 1,1-<br>
dimethylethyl ester as a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-1-benzyl-3-<br>
(2-indanylamino)-2-hydroxy-3-oxopropyl)carbamic acid 1,1-<br>
dimethylethyl ester in place of ((1S)-1-benzyl-3- ethylamino-<br>
2-hydroxy-3-oxo- propyl)carbamic acid 1,1-dimethylethyl ester,<br>
there was obtained (3S) -3-amino-2-hydroxy-N- (2-indanyl) -4-<br>
phenylbutanamide hydrochloride as a white solid.<br>
M.p. 183.0-184.8°C<br>
1H-NMR(300MHz ,DMSO-d6) δ 2 . 76-2.96(m,4H),3.01-3.18(m,2H),<br>
3.62(m,0.5H),3.74(m,0.5H),3.92(m,0.5H),4.25-4.39(m,1H),<br>
4.49(m,0.5H),6.48(d,0.5H,J=5.7),6.72(d,0.5H,J=5.7),7.13-<br>
7.35(m,9H),8.15(m,3.5H),8.26(d,0.5H,J=7.2).<br>
Reference Example 15<br>
(3S)-3-Amino-2-hydroxy-N- (2-methoxyethyl) - 4 -<br>
phenylbutanamide hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using methoxyethylamine in place of<br>
aqueous ethylamine, there was obtained ((1S)-1-benzyl-2-<br>
hydroxy-3-(2-methoxyethyl)-3-oxopropyl)carbamic acid 1,1-<br><br>
dimethylethyl ester as a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-1-benzyl-2-<br>
hydroxy-3-(2-methoxyethyl)-3-oxopropyl)carbamic acid 1,1-<br>
dimethylethyl ester in place of ((1S)-1-benzyl-3-<br>
ethylamino-2-hydroxy-3-oxopropyl)carbamic acid 1,1-<br>
dimethylethyl ester, there was obtained ((3S)-3-amino-2-<br>
hydroxy-N- ( 2-methoxyethyl) -4-phenylbutanamide hydrochloride<br>
as a white solid.<br>
M.p. 113.9-117.7°C<br>
1H-NMR(300MHz ,DMSO-d6) δ 2.82(d, 1H, J=6.6 ),2.95 (m, 1H) , 3 .10-<br>
3.19(m,2H),3.22(s,1.5H),3.23(s,1.5H),3.28-3.34(m,2H),3.57<br>
(m,0.5H),3.70(m,0.5H),3.92(m,0.5H),4.32 (m,0.5H),6.59(d,<br>
0.5H,J=4.5),6.87(d,0.5H,J=6.0),7.22-7.36(m,5H),7.92 t,0.5H,<br>
J=5.7),7.98(t.0.5H,J=5.1),8.09(br s,1.5H),8.24(br s,1.5H).<br>
Reference Example 16<br>
(3S)-3-Amino-N-ethyl-2-hydroxy-5-phenylpentanamide<br>
hydrochloride<br>
(1) To a solution of Boc-1-homophenylalanine (20 g, 72<br>
mmol) in dlmethoxyethane (100 mL) were added N-methylmorpholine<br>
(7.2 g, 72 mmol) and isobutyl chloroformate (9.8 g, 72 mmol)<br>
in an ice-salt bath. After 1 hour with stirring, the reaction<br>
mixture was filtered and the filtrate was cooled in an ice-salt<br>
bath, and a solution of NaBH4 (4.1 g, 107 mmol) in water (10<br>
mL) was added, followed by water (300 mL) . The resultant<br>
precipitates were collected by filtration, and the residue was<br>
washed with water and methanol to give<br>
N- (tert-butoxycarbonyl)-1-homo-phenylalaninol (15 g, 79%) as<br><br>
colorless crystals.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 8(2) and using N-(tert-butoxycarbonyl)-1-<br>
homophenylalaninol in place of N- (tert-butoxycarbonyl)-<br>
L-phenylalaninol, there was obtained N- (tert-butoxycarbonyl) -<br>
L-phenylalaninal as a colorless oil.<br>
(3)	Following the reaction in an analogous manner to<br>
Reference Example 8(3) and using N-(tert-butoxycarbonyl)-<br>
L-homophenylalaninal in place of N- (tert-butoxycarbonyl)-<br>
L-homophenylalaninal, there was obtained (3S)-3-amino-2-<br>
hydroxy-5-phenylpentanoic acid as a white solid.<br>
(4)	Following the reaction in an analogous manner to<br>
Reference Example 8(4) and using (3S)-3-amino-2-hydroxy-<br>
5-phenylpentanoic acid in place of (3S)-3-amino-2-hydroxy-<br>
4-phenylbutyric acid, there was obtained<br>
(3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-5-<br>
phenylpentanoic acid as a colorless oil.<br>
(5) Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using (3S)-3-(tert-<br>
butoxycarbonylamino) -2-hydroxy-5-phenylpentanoic acid in<br>
place of (3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-<br>
phenylbutanoic acid, there was obtained ((1S)-3-<br>
ethylamino-2-hydroxy-3-oxo-1-(phenylethyl)propyl)carbamic<br>
acid 1,1-dimethylethyl ester as a white solid.<br>
(6) Following the reaction in an analogous manner.to<br>
Reference Example 8(6) and using (1S)-3-ethylamino-2-<br>
hydroxy-3-oxo-1-(phenylethyl)propyl)carbamic acid 1,1-<br>
dimethylethyl ester in place of ((1S)-1-benzyl-3-<br>
ethylamino-2-hydroxy-3-oxopropyl)carbamic acid 1,1-<br><br>
dimethylethyl ester, there was obtained (3S) -3-amino-<br>
N-ethyl-2-hydroxy-5-phenylpentanamide hydrochloride as a<br>
white solid.<br>
M.p. 134.4-134.9°C<br>
1H-NMR(300 MHz ,DMSO-d6) δ 0 . 99-1. 06 (m, 3H) , 1. 65-1. 96 (m, 2H) ,<br>
2.54-2.76(m,2H),3.07-3.23(m,2H),4.15(br s,0.5H),4.25(br s,<br>
0.5H),6.44(br s,0.5H),6.55(br s,0.5H),7.17-7.33(m,5H).7.99<br>
(br s,1.5H),8.15(t,1H,J=6.2),8.23(br s,1.5H).<br>
Reference Example 17<br>
(3S) -3-Amino-N-cyclopropyl-2-hydroxy-5~phenylpentanamide<br>
hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 16(5) and using cyclopropylamine in place of<br>
aqueous ethylamine, there was obtained ((1S)-3-<br>
cyclopropylamino-2-hydroxy-3-oxo-1-<br>
(phenylethyl)propyl)carbamic acid 1,1-dimethylethyl ester as<br>
a white solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 16(6) and using ((1S)-3-cyclopropylamino-<br>
2-hydroxy-3-oxo-1-(phenylethyl)propyl)carbamic acid 1,1-<br>
dimethylethyl ester in place of ((1S)-1-benzyl-3-ethylamino-<br>
2-hydroxy-3-oxopropyl)carbamic acid 1,1-dimethylethyl ester,<br>
there was obtained (3S)-3-amino-N-cyclopropyl-2-<br>
hydroxy-5-phenylpentanamide hydrochloride as a white solid.<br>
M.p. 140.2-141.3°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.46-0.64(m,4H),1.64-1.99(m,2H) ,<br>
2.54-2.78(m,3H),3.35(m,1H),4.13(br s,0.5H),4.26(br s,0.5H),<br>
6.37(br s,0.5H),6.51(br s,0. 5H) , 7.17-7.33(m,5H),8.05(br s.<br><br>
1.5H),8.15(d,0.5H,J=4.5 ) ,8.20(d,0.5H,J=4.8),8.27(br s,<br>
1.5H).<br>
Reference Example 18<br>
(3S) -3-Amino-2-hydroxy-5-methyl-N-( 2-phenoxyethyl) -<br>
hexanamide hydrochloride<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 8(1) and using L-leucinol in place of<br>
L-phenylalaninol, there was obtained N- (tert-butoxycarbonyl) -<br>
L-leucinol (70 g, 84 %) as a colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 8(2) and using N-(tert-butoxycarbonyl)-<br>
L-leucinol in place of N-(tert-butoxycarbonyl)-1-<br>
phenylalaninol, there was obtained N-(tert-butoxycarbonyl)-<br>
L-leucinal as a colorless oil.<br><br>
(3)	Following the reaction in an analogous manner to<br>
Reference Examples 8(3) and 8(4) and using N-(tert-<br>
butoxycarbonyl)-1-leucinal in place of N-(tert-<br>
butoxycarbonyl)-1-phenylalaninal, there was obtained (3S)-<br>
3-(tert-butoxycarbonylamino)-2-hydroxy-5-methylhexanoic<br>
acid as a colorless oil.<br>
(4)	Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using (3S)-3-(tert-<br>
butoxycarbonylamino ) -2-hydroxy- 5 -methylhexanoic acid in<br>
place of (3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-<br>
4-phenylbutanoic acid, and 2-phenoxcyethylamine in place of<br>
aqueous ethylamine, there was obtained ((1S)-2-hydroxy-1-<br>
(2-methylpropyl)-3-oxo-3-(2-phenoxyethyl)amino-<br>
propyl)carbamic acid 1,1-dimethylethyl ester as a colorless<br><br>
oil.<br>
(5) Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using ((1S)-2-hydroxy-1-(2-<br>
methylpropyl) - 3 - oxo - 3 - ( 2 -phenoxyethyl) aminopropy 1) carbamic<br>
acid 1,1-dimethylethyl ester in place of ((1S)-1-benzyl-3-<br>
ethylamino-2-hydroxy-3-oxopropyl) carbamic acid 1,1-<br>
dimethylethyl ester, there was obtained the title compound as<br>
a white solid.<br>
M.p. 93.6-96.2°C<br>
1H-NMR( 300MHz,DMSO-d6) δ 0 . 71-0 . 89 (m, 6H) , 1. 35-1. 47 (m, 2H) ,<br>
1.72(m,1H),3.48-3.54(m,4H),4.00-4.07(m,2H),4.12(d,0.5H,J=<br>
3.6) ,4.33(d,0.5H,J=1.8),6.91-6.96(m,3H),7.27-7.32(m,2H),<br>
7.95(br s,1.5H),8.19-8.29(m,2.5H).<br>
Reference Example 19<br>
3-Amino-2-hydroxy-5-phenylpentanamide hydrochloride<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(5) and using ammonia gas in place of aqueous<br>
ethylamine, there was obtained l-benzyl-3-amino-2-hydroxy-<br>
3-oxopropyl)carbamic acid 1,1-dimethylethyl ester as a white<br>
solid.<br>
Following the reaction in an analogous manner to<br>
Reference Example 8(6) and using (1-benzyl-3-amiino—2-<br>
hydroxy—3-oxopropyl)carbamic acid 1,1-dimethylethyl ester in<br>
place of ((1S)~l-benzyl-3-ethylamino-2-hydroxy-3-oxo-<br>
propyl)carbamic acid 1,1-dimethylethyl ester, there was<br>
obtained the title compound as a white solid.<br>
1H-NMR(300MHz,DMSO-d6) δ 2.82(m,1H),2.93(m,1H),3.61(m,1H),<br>
3.85(m,0.5H),4.26(m,0.5H),6.48(d,0.5H,J=4.8),6.75(d,0.5H,<br><br>
J=5.7),7.24-7.35(m,5H),7.52(m,2H),8.04(brs,1.5H),8.17(brs,<br>
1.5H).<br>
Reference Example 20<br>
N-((2-(Pyridine-2-yl)ethyl)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using (2-pyridyl)ethanol in place<br>
of (S)-3-hydroxytetrahydrofuran, there was obtained<br>
N-succinimidyl 2-(pyridin-2-yl)ethylcarbonate as a brown oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using N-succinimidyl<br>
2-(pyridin-2-yl)ethylcarbonate in place of N-succinimidyl<br>
(3S)-3-tetrahydrofuranyl carbonate, there was obtained<br>
N-{ (2- (pyridin-2-yl)ethyloxy)carbonyl) -1-leucine ethyl ester<br>
as a colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N- ((2-(pyridin-2-<br>
yl)ethyloxy)carbonyl)-1-leucine ethyl ester in place of<br>
W-(((S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine ethyl<br>
ester, there was obtained N-((2-(pyridin-2-<br>
yl)ethyloxy)carbonyl)-1-leucine as a white solid.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N-((2-(pyridin-2-<br>
yl)ethyloxy)carbonyl)-1-leucine in place of N-((2-<br>
methoxyethoxy)carbonyl-L-leucine, there was obtained the<br>
title compound as a colorless oil.<br>
1H-NMR(300 MHz,DMSO-d6) δ 0 . 82-0 . 91(m, 6H) , 1. 42-1. 76 (m, 3H) ,<br>
2. 76-2.81(m,4H),3.00-3.06 (m,2H),4.30-4.40(m,3H),7.23(dd,1H,<br><br>
J=7.1,5.3),7.30(d,1H,J=7.8),7.71(m,1H),7.90 (d,1H,J=8.1),<br>
8.50(d,1H,J=4.5).<br>
Reference Example 21<br>
N-((2-(6-Methylpyridin-2-yl)ethyloxy)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1) Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using<br>
2-(6-methylpyridin-2-yl)ethanol in place of<br>
(S)-3-hydroxytetrahydrofuran, there was obtained<br>
N-succinimidyl 2-(6-methylpyridin-2-yl)ethylcarbonate as a<br>
brown oil.<br>
(2) Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using N-succinimidyl<br>
2-(6-methylpyridin-2-yl)ethylcarbonate in place of<br>
N-succinimidyl (3S)-3-tetrahydrofuranyl carbonate, there was<br>
obtained N-((2-(6-methylpyridin-2-yl)ethyloxy)carbonyl)-1-<br>
leucine ethyl ester as a colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N- ((2-(6-methylpyridin-2-<br>
yl)ethylbxy)carbonyl)-1-leucine ethyl ester in place of<br>
N- (((3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine ethyl<br>
ester, there was obtained N-((2-(6-methylpyridin-2-<br>
yl)ethyloxy)carbonyl)-1-leucine as a colorless oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using<br>
N-((2-(6-methylpyridin-2-yl)ethyloxy)carbonyl)-1-leucine in<br>
place of N-((2-methoxyethoxy)carbonyl)-1-leucine, there was<br>
obtained the title compound as a colorless oil.<br><br>
1H-NMR (300 MHz, DMSO-d6) δ 0.83-0.92 (m, 6H) , 1.49-1.77 (m,<br>
3H), 2.43 (s, 3H) , 2.81 (s, 4H) , 2.99 (t, 2H, J = 6.5), 4.29-4.42<br>
(m, 3H), 7.07-7.09 (m, 2H) . 7.58 (t, 1H, J = 7.7), 7.91 (d, 1H,<br>
J = 8.4) .<br>
Reference Example 22<br>
N-((2-(5-Ethylpyridin-2-yl)ethyloxy)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using (5-ethylpyridin-2-yl)ethanol<br>
in place of (S)-3-hydroxytetrahydrofuran, there was obtained<br>
N-succinimidyl 2-(5-ethylpyridin-2-yl)ethylcarbonate as a<br>
brown oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using N-succinimidyl<br>
2-(5-ethylpyridin-2-yl)ethylcarbonate in place of<br>
N-succinimidyl (3S)-3-tetrahydrofuranyl carbonate, there was<br>
obtained N-((2-(5-ethylpyridin-2-yl)ethyloxy)carbonyl)-1-<br>
leucine ethyl ester as a colorless oil.<br>
(3)	Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using<br>
N-(((2-(5-ethylpyridin-2-yl)ethyloxy)carbonyl)-1-leucine<br>
ethyl ester in place of N-(((3S)-tetrahydrofuran-3-<br>
yloxy)carbonyl)-1-leucine ethyl ester, there was obtained<br>
N-((2-(5-ethylpyridin-2-yl)ethyloxy)carbonyl)-1-leucine as a<br>
colorless oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N- ((2-(5-ethylpyridin-2-<br>
yl)ethyloxy)carbonyl)-1-leucine in place of N-((2-<br><br>
methoxyethoxy)carbonyl)-1-leucine, there was obtained the<br>
title compound, as a colorless oil.<br>
1H-NMR (300 MHz, DMSO-d6) δ 0.75-0.92 (m, 6H) , 1.12-1.25 (m,<br>
3H), 1.36-1.72 (m, 3H), 2.54-2.63 (m, 2H), 2.81-2.83 (m, 4H) ,<br>
2.96-3.02 (m, 2H), 4.04 (m, 1H), 4.29-4.37 (m, 2H) , 7.21 (d,<br>
1H, J = 7.8), 7.53 (m, 1H) , 7.90 (d, 1H, J = 7.8) , 8.34 (m, 1H) .<br>
Reference Example 23<br>
N-((2-tert-Butoxyethyloxy)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using ethylene glycol tert-butyl<br>
ether in place of (S)-3-hydroxytetrahydrofuran, there was<br>
obtained N-succinimidyl 2-tert-butoxyethyl carbonate as a<br>
colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using N-succinimidyl<br>
2-tert-butoxyethyl carbonate in place of N-succinimidyl<br>
(3S)-3-tetrahydrofuranyl carbonate, there was obtained<br>
N-((2-tert-butoxyethyloxy)carbonyl)-1-leucine ethyl ester as<br>
a colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using N-((2-tert-<br>
butoxye thyloxy) carbonyl)-1-leucine ethyl ester in place of<br>
N-(((3S)-tetrahydrofuran-3-yloxy)carbonyl)-1-leucine ethyl<br>
ester, there was obtained N-((2-tert-<br>
butoxye thyloxy) carbonyl) -1-leucine as a colorless oil.<br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using<br><br>
N-((2-tert-butoxyethyloxy) carbonyl) -1-leucine in place of<br>
N-((2-methoxyethyloxy)carbonyl)-1-leucine, there was<br>
obtained the title compound as a colorless oil.<br>
1H-NMR(300 MHz, DMSO-d6) δ 0.89 (d, 3H, J = 6.3), 0.92 (d, 3H,<br>
J = 6.3), 1.13 (s, 9H), 1.61 (m, 1H), 1.74 (m, 2H), 2.81 (s,<br>
4H), 3.48 (t, 2H, J = 4.7), 4.04 (m, 2H), 4.40 (m, 1H), 8.00<br>
(d, 1H, J = 7.8).<br>
Reference Example 24<br>
N-((2-Isopropoxyethyloxy)carbonyl)-1-leucine<br>
N-hydroxysuccinimide ester<br>
(1)	Following the reaction in an analogous manner to<br>
Reference Example 2(1) and using ethylene glycol isopropyl<br>
ether in place of (S)-3-hydroxytetrahydrofuran, there was<br>
obtained N-succinimidyl 2-isopropoxyethyl carbonate as a<br>
colorless oil.<br>
(2)	Following the reaction in an analogous manner to<br>
Reference Example 2(2) and using N-succinimidyl<br>
2-isopropoxyethyl carbonate in place of N-succinimidyl<br>
(3S)-3-tetrahydrofuranyl carbonate, there was obtained<br>
N-((2-isopropoxyethyloxy) carbonyl)-1-leucine ethyl ester as a<br>
colorless oil.<br>
(3) Following the reaction in an analogous manner to<br>
Reference Example 2(3) and using<br>
 N-((2-isopropoxyethyloxy)carbonyl)-1-leucine ethyl ester in<br>
place of N-(((3S)-tetrahydrofuran-3-yloxy)carbonyl)-<br>
L-leucine ethyl ester, there was obtained<br>
N-((2-isopropoxyethyloxy)carbonyl)-1-leucine as a colorless<br>
oil.<br><br>
(4) Following the reaction in an analogous manner to<br>
Reference Example 1(2) and using N-{{2-<br>
isopropoxyethyloxy)carbonyl)-1-leucine in place of N-{{2-<br>
methoxyethyloxy)carbonyl)-1-leucine, there was obtained the<br>
title compound as a colorless oil.<br>
1H-NMR (300 MHz, DMSO-d6) δ 0.89 (d, 3H, J = 6.6) , 0.92 (d, 3H,<br>
J = 6.3), 1.08 (d, 6H, J = 6.3), 1.61 (m, 1H), 1.74 (m, 2H),<br>
2.81 (s, 4H), 3.53 (m, 2H), 3.57 (m, 1H), 4.07 (m, 2H), 4.40<br>
(m, 1H), 8.02 (d, 1H, J = 7.8).<br>
Example 1<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(ethylamino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 1)<br><br>
To a solution of the compound of Reference Example 1(1.2<br>
g, 3.6 mmol) and the compound of Reference Example 8 (1.0 g,<br>
4.0 mmol) in DMF was added triethylamine (1.1 g, 11 mmol, 1.5<br>
mL) . The mixture was stirred at room temperature for 18 hours,<br>
and concentrated in vacuo. The residue was dissolved in ethyl<br>
acetate (EtOAc), and the solution was washed with 1M HCl,<br>
saturated aqueous NaHCO3 and saturated aqueous NaCl, dried over<br>
anhydrous MgSO4, and concentrated in vacuo. The resulting<br>
white solid was washed with a mixture of EtOAc and hexane (1 :<br><br>
9) to give ((1S) -1- ((( (1S) -1-benzyl-3-ethylamino-2-hydroxy-<br>
3-oxopropyl)amino)carbonyl) -3-methylbutyl)carbamic acid.<br>
2-methoxyethyl ester (0.75 g, 47%) as a white solid.<br>
To a solution of ((1S)-1-((((1S)-1-benzyl-3-ethylamino-<br>
2-hydroxy-3-oxo-propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (0.7 g, 1.6<br>
mmol) in CH2Cl2 (70 mL) was added Dess-Martin periodinane (1.0<br>
g, 2.4 mmol) . The mixture was stirred at room temperature for<br>
18 hours. Aqueous 10% Na2S203 (35 mL) and saturated aqueous<br>
NaHCO3 (35 mL) were added thereto, and the mixture was stirrer<br>
at room temperature for 30 minutes. The organic layer was<br>
separated, washed with 1M HCl, saturated aqueous NaHCO3 and<br>
saturated aqueous NaCl, dried over MgSO4, and concentrated in<br>
vacuo. The residue was crystallized from EtOAc/hexane to give<br>
the title compound (0.62 g, 88%) as colorless crystals. M.p.<br>
138.0-138.3°C.<br>
1H-NMR(300 MHz, DMSO-d6) δ 0 . 83(d,3H,J=7.5),0.85(d,3H,J=7.2)<br>
1.04(t,3H,J=7.1),1.35(m,2H),1.56(m,1H),2.82(m,1H),3.14(m,<br>
3H),3.25(s,3H),3.47(t,2H,J=4.5),4.04(m,3H),5.19(m,1H),<br>
7.16-7.33(m,6H),8.24(d,1H,J=7.2),8.70(m,1H).<br>
MALDI-TOF-MS calcd for C22H33N3O6 (M+Na) + , 458.2267, Fount<br>
458.2361.<br>
Example 2<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(ethylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic<br>
acid (3S)-tetrahydrofuran-3-yl ester (Compound 2)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 2 in place of<br>
the compound of Reference Example 1, there was obtained the<br>
title compound as colorless crystals, via ((1S)-1-((((1S)-1-<br>
benzyl- 3 -ethylamiino—2 -hydroxy- 3 -oxopropyl) amino) carbonyl) -<br>
3-methylbutyl)carbamic acid (3S)-tetrahydrofuran-3-yl ester.<br>
M.p. 158.9-160.7°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.83(d,3H,J=6.6),0.85(d,3H,J=6.9),<br>
1.04(t,3H,J=7.1),1.35(m,2H),1.55(m,1H),1.83(m,1H),2.08(m,<br>
1H),2.82(m,1H),3.14(m,3H),3.61-3.78(m,4H),4.01(m,1H),5.07<br>
(m,1H),5.19(m,1H),7.17-7.33(m,6H),8.22(d,1H,J=7.2),8.69(t,<br>
1H,J=5.7).<br>
MALDI-TOF-MS:C23H33N3O6(M+H)+ , 448.2447, Found: 448 .2509 .<br>
Example 3<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(ethylamino) propyl) amino) carbonyl) - 3 -methylbutyl) carbamic<br>
acid tetrahydro-4H-pyran-4-yl ester (Compound 3)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 3 in place of the<br>
compound of Reference Example 1, there was obtained the title<br>
compound as colorless crystals, via ((1S)-1-((((1S)-1-<br>
benzyl- 3 -ethylamino - 2 -hydroxy- 3 -oxopropyl) amino) carbonyl) -<br>
3-methylbutyl)carbamic acid tetrahydro-4H-pyran-4-yl ester.<br>
M.p. 140.0-141.8°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.84(m,6H),1.04(t,3H,J=7.2),1.35 (m,<br>
2H),1.49(m,3H),1.79(m,2H),2.82 (m,1H),3.14(m,3H),3.41(m,2H),<br>
3.78(m,2H),4.02(m,1H) ,4.66(m,1H),5.19(m,1H),7.15-7.33(m,<br>
6H),8.22(d,1H,J=7.2), 8.69(t,1H,J=5.7).<br>
MALDI-TOF-MS:C24H35N3O6(M+Na)+ , 484.2424, Found: 484.2486.<br>
Example 4<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 4)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 9 in place of the<br>
compound of Reference Example 8, there was obtained the title<br>
compound as colorless crystals, via<br>
( (1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2-hydroxy-<br>
3-oxo-propyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-methoxyethyl ester.<br>
M.p. 112.4-113.5°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0 . 58(m, 2H) , 0 . 65 (m, 2H) , 0 . 83 (d, 3H,<br>
J=6.6),0.85(d,3H,3=6.6),1.35(m,2H),1.56(m,1H),2.68-2.88<br>
(m,2H),3.11(m,1H),3.25(s,3H),3.47(t,2H,J=4.5),4.04(m,3H),<br>
5.l7(m,1H),7.17-7.34(m,6H),8.25(dr1H,J=7.2),8.73(d,1H,<br>
J=4.8).<br>
MALDI-TOF-MS:C23H33N306(M+Na) + , 470 . 2267 ,	Found: 470 . 2441.<br>
[α]D25+6.3° (c0.20,DMSO)<br>
Example 5<br>
((1S)-1-((((1S)-1-Benzyl-3-(cyclopropylamino)-2,3-dioxo-<br>
propyl)amino)carbonyl)-3-methylbutyl)carbamic acid (3S)-<br>
tetrahydrofuran-3-yl ester (Compound 5)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 2 in place of the<br>
compound of Reference Example 1, and the compound of Reference<br><br>
Example 9 in place of the compound of Reference Example 8, there<br>
was obtained the title compound as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
(3S)-tetrahydrofuran-3-yl ester.<br>
M.p. 169.2-170.5°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.58(m,2H),0.65(m,2H),0.83(d,3H,<br>
J=8.1),0.85(d,3H,J=6.9),1.34(m,2H),1.55(m,1H),1.83(m,1H),<br>
2.08(m,1H),2.79(m,2H),3.12(m,1H),3.61-3.80(m,4H),4.02 (m,<br>
1H),5.08(m,1H),5.17(m,1H),7.22-7.35(m,6H),8.24(d,1H,J=6.6),<br>
8.74(d,1H,J=5.1).<br>
MALDI-TOF-MS:C24H33N3O6(M+Na)+, 482.2267, Found: 482.2586.<br>
Example 6<br>
((1S)-1-((((1S)-1-Benzyl-3-cyclopropylamino-2,3-<br>
dioxo-propyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
tetrahydro-4H-pyran-4-yl ester (Compound 6)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 3 in place of the<br>
compound of Reference Example 1, and the compound of Reference<br>
Example 9 in place of the compound of Reference Example 8, there<br>
was obtained the title compound as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2-hydroxy-3-<br><br>
oxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
tetrahydro-4H-pyran-4-yl ester.<br>
M.p. 137.0-138.2°C<br>
1H-NMRt 300MHz, DMSO-d6) 6 0 . 58 (m, 2H) , 0 . 65 (m, 2H) , 0 . 84(m, 6H) .<br>
1.35(ra 2H) ,1.48(m,3H),1.80(m,2H),2.79(m,2H),3.11(m,1H),3.41<br>
(m,2H),3.79(m,2H),4.03(m,1H),4.65(m,1H),5.18(m,1H),7.15-<br>
7.30(m,6H) ,8.23(d,1H,J=6.9),8.73(d,1H,J=5.4).<br>
MALDI-TOF-MS:C25H35N306(M+H)+ , 474.2604, Found: 474.2643.<br>
Example 7<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
( propylamino) propyl) amino) carbonyl) - 3 -methylbutyl) carbamic<br>
acid 2-methoxyethyl ester (Compound 7)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 10 in place of<br>
the compound of Reference Example 8, there was obtained the<br>
title compound as colorless crystals, via ((1S)-1-((((1S)-<br>
1-benzyl-2-hydroxy-3-oxo-3-<br>
(propylamino)propyl) amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester.<br>
M.p.l08.8-109.9°C<br>
1H-NMR(30 MHz,DMS0-d6) δ 0.83(m,9H),1.35(m,2H),1.46(m,2H),<br>
1.55(m,1H),2.83(dd,1H,J=14.0,9.2),3.08(m,3H),3.25(s,3H),<br><br>
3.48(t,2H,J=4.4),4.04(m,3H),5.19(m,1H),7.22-7.28(m,6H),<br>
8.24(d,1H,J=6.9),8.68(t,1H,J=5.6).<br>
MALDI-TOF-MS:C23H35N3O6(M+H) + , 450.2604, Found: 450.2832.<br>
Example 8<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(cyclobutylamino) propyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 8)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 11 in place of<br>
the compound of Reference Example 8, there was obtained the<br>
title compound as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-cyclobutylamino-2-hydroxy-3-<br>
oxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
2-methoxyethyl ester.<br>
M.p. 114.2-115.3°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.84(m, 6H),1.34(m,2H),1.49-1.72(m,<br>
3H),2.10(m,4H),2.81(dd,1H,J=13.8,9.3),3.10(m,1H),3.25(s,<br>
3H),3.47(m,2H),4.03(m,3H),4.22(m,1H),5.15(m,1H),7.24(m,6H),<br>
8.24(d,1H,J=7.2),8.91(d,1H,J=7.8).<br>
MALDI-TOF-MS:C24H35N3O6(M+Na)+ , 484.2424, Found: 484.2400.<br>
Example 9<br><br>
((1S)-1-((((1S)-1-Benzyl-3-butylamino-2,3-dioxo-<br>
propyl)amino)carbonyl)-3-methylbutyl)carbamic	acid<br>
2-methoxyethyl ester (Compound 9)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 12 in place of<br>
the compound of Reference Example 8, there was obtained the<br>
title compound as colorless crystals, via ((1S)-1-((((1S)-<br>
1-benzyl-3-butylamino-2 -hydroxy- 3 -oxopropyl) amino) carbonyl)<br>
-3-methylbutyl)carbamic acid 2-methoxyethyl ester.<br>
M.p. 94.0-95.2°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.85(m,9H),1.25(m,2H),1.35(m,2H),<br>
1.42(m,2H),1.56(m,1H),2.83(dd,1H,J=13.8,9.0),3.10(m,3H),<br>
3.25(s,3H),3.47(t,2H,J=4.5),4.04(m,3H),5.l8(m,1H),7.21-<br>
7.29(m,6H),8.23(d,1H,J=6.6),8.67(t,1H,J=6.0).<br>
MALDI-TOF-MS:C24H37N3O6(M+H)+ , 464.2760, Found: 464 . 2870 .<br>
Example 10<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-(2,2,2-<br>
trifluoroethylamino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 10)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 13 in place of<br>
the compound of Reference Example 8, there was obtained the<br>
title compound as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-2-hydroxy-3-oxo-3-(2,2,2-<br>
trifluoroethyl-amino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester.<br>
M.p. 152.5-153.9°C<br>
1H-NMR(300MHz, DMSO-d6) δ 0.84(m,6H),1.34(m,2H),1.55(m,1H),<br>
2.86(dd,1H,J=14.0,8.6),3.10(dd,1H,J=14.1,4.8),3.25(s,3H),<br>
3.48(t,2H,J=4.7),3.90(m,2H),4.04(m,3H),5.14(m,1H),7.21-<br>
7.31(m,6H),8.34(d,1H,J=6.9),9.29(m,1H).<br>
MALDI-TOF-MS:C22H3oF3N3O6(M+H)+ , 490.2165, Found: 490.2434.<br>
Example 11<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-(2-<br>
indanylamino)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 11)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 14 in place of<br>
the compound of Reference Example 8, there was obtained the<br>
title compound as colorless crystals, via ((1S)-1-((((1S)-<br>
1-benzyl-2-hydroxy-3-(2-indanylamino)-3-<br>
oxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
2-methoxyethyl ester.<br>
M.p. 141.9-143.5°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.83(d,3H,J=6.9),0.86(d,3H,J=6.9),<br>
1.36(m,2H),1.57(m,1H),2.80-2.96(m,3H),3.10-3.18(m,3H),3.24<br>
(s,3H),3.47(t,2H,J=4.7),4.04(m,3H),4.50(m,1H),5.19(m,1H),<br>
7.13-7.30(m,10H),8.29(d,1H,J=6.9),8.97(d,1H,J=7.2).<br>
MALDI-TOF-MS:C29H37N3O6(M+H) + , 524.2760, Found: 524.2810.0<br>
Example 12<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-(2-<br>
methoxyethylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 12)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 15 in place of<br>
the compound of Reference Example 8, the title compound was<br>
obtained as colorless crystals, via ((1S)-1-((((1S)-1-benzyl-<br>
2-hydroxy-3- (2-methoxyethylamino) -3-oxopropyl)amino)carbonyl)<br><br>
-3-methylbutyl)carbamic acid 2-methoxyethyl ester<br>
M.p. 127.0-127.9°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.83(d,3H,J=6.9),0.86(d,3.J=6.9),<br>
1.35(m,2H),1.56(m,1H),2.83(dd,1H,J=13.8,9.0),3.11(dd,1H,J=l<br>
4.0,4.4),3.24(s,3H),3.25(s,3H),3.16-3.34(m,2H),3.39(m, 2H),3<br>
.48(t,2H,J=4.5),4.04(m,3H),5.20(m,1H),7.18-7.30(m,6H),8.21(<br>
d,1H,J=6.9),8.66(t,1H,J=5.4).<br>
MALDI-TOF-MS :C23H35N3O7(M+Na) + , 488 . 2373 , Found: 488 . 2680 .<br>
Example 13<br>
((1S)-1-((((1S)-2,3-Dioxo-3-ethylamino-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 13)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 16 in place of<br>
the compound of Reference Example 8, the title compound was<br>
obtained as colorless crystals, via ((1S)-1-((((1S)-3-<br>
ethylamino-2-hydroxy-3-oxo-1-<br>
(phenylethyl)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester.<br>
M.p. 119.1-120.4°C<br>
1H-NMR( 300MHz,DMSO-d6) δ 0.89(t,6H,J=6.3),1.03(t,3H,J=7.2) ,<br><br>
1.43(t,2H,J=7.2).1.61-1.85(m,2H),2.07(m,1H),2.56-2.74<br>
(m,2H),3.07-3.17(m,2H),3.25(s,3H),3.49(t,2H,J=4.7),4.05-<br>
4.14(m,3H),4.89(m,1H),7.16-7.36(m,5H),7.34(d,1H,J=8.4),<br>
8.33(d,1H,J=6.9),8.65(t,1H,J=5.9).<br>
MALDI-TOF-MS:C23H35N3O6(M+H)+, 450 . 2604 ,Found: 450. 2701.<br>
Example 14<br>
((1S)-1-((((1S)-2,3-Dioxo-3-ethylamino-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-<br>
methylbutyl) carbamic acid (3S)-tetrahydrofuran-3-yl ester<br>
(Compound 14)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 2 and 16 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-3-ethylamino-2-hydroxy-3-oxo-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-methylbutyl)carbamic<br>
acid (3S)-tetrahydrofuran-3-yl ester.<br>
M.p. 111.9-114.5°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0 . 89 (t, 6H , J=6 . 3) , 1. 03 (t, 3H, J=7.2),<br>
1.43(t,2H,J=7.4),1.60-1.91(m,3H),2.09(m,2H),2.56-2.76(m,<br>
2H),3.07-3.17(m,2H),3.63-3.82(m,4H),4.02-4.13(m,1H),4.88<br><br>
(m,1H), 5.09-5.13(m,1H),7.16-7.31(m,5H),7.34(d,1H,J=8.4),8.3<br>
4(d,1H,J=6.9),8.66(t,1H,J=5.7).<br>
MALDI-TOF-MS:C24H35N3O6(M+H) + , 462. 2604,Found: 462. 2870.<br>
Example 15<br>
((1S)-1-((((1S)-2,3-Dioxo-3-cyclopropylamino-1-<br>
(phenylethyl) propyl) amino) carbonyl) - 3 -methylbutyl} carbamic<br>
acid 2-methoxyethyl ester (Compound 15)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Example 17 in place of<br>
the compound of Reference Example 8, the title compound was<br>
obtained as colorless crystals, via ((1S)-1-((((1S)-3-<br>
cyclopropylamino-2-hydroxy-3-oxo-1-<br>
(phenylethyl)propyl)amino)carbonyl)-3-methylbutyl)carbamic<br>
acid 2-methoxyethyl ester<br>
M.p. 109.7-111.1°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.53-0.68(m, 4H),0.87-0.91(m,6H),<br>
1.43(t,3H,J=7.2),1.59-1.85(m,2H),2.01-2.13(m,1H),2.56-2.74<br>
(m,3H),3.25(s,3H),3.48-3.51(m,2H),4.05-4.14(m,3H),4.87(m,lH<br>
),7.17-7.36(m,6H),8.34(d,1H,J=6.6),8.69(d,1H,J=5.1).<br>
MALDI-TOF-MS:C24H35N3O6(M+H)+ , 462. 2604, Found :462.2742.<br><br>
Example 16<br>
((1S)-1-((((1S)-2,3-Dioxo-3-cyclopropylamino-1-<br>
(phenylethyl)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid (3S)-tetrahydro-furan-3-yl ester<br>
(Compound 16)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 2 and 17 in<br>
place of the compounds of Reference Examples 1 and 8<br>
respectively, the title compound was obtained as colorless<br>
crystals, via ((1S)-1-((((1S)-3-cyclopropylamino-2-hydroxy-<br>
3-oxo-1-(phenylethyl)propyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid (3S)-tetrahydrofuran-3-yl ester.<br>
M.p. 115.8-116.2°C<br>
1H-NMR(300MHzDMSO-d6) δ 0.56-0.59(m,4H),0.88(t,6H,J=6.3),<br>
1.42(t,2H,J=7.4),1.60-1.91(m,3H),2.09(m,2H),2.56-2.76(m,<br>
3H),3.63-3.81(m,4H),4.05-4.13(m,1H),4.87(m,1H),5.09-5.13(m,<br>
1H),7.20-7.35(m,6H),8.34(d,1H,J=6.9),8.69(d,1H,J=5.1).<br>
MALDI-TOF-MS:C25H35N3O6(M+H) + , 474. 2604,Found: 474 . 2598 .<br>
Example 17<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br><br>
methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester<br>
(Compound 17)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 4 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2-hydroxy-3-<br>
oxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
5-methoxy-3-oxapentyl ester.<br>
M.p. 127.9-128.7°C<br>
1H-NMR(300MHzDMSO-d6) δ 0 . 54-0 . 66 (m, 4H) , 0 . 81-0 . 86 (m, 6H) ,<br>
1.30-1-42(m,2H),1.57(m, 1H),2.73(m,1H),2.82(dd,1H,J=14.3,<br>
9.2),3.11(dd,1H,J=13.8,4.2),3.24(s,3H),3.42-3.44(m,2H),<br>
3.50-3.57(m,4H),3.99-4.04(m,3H),5.17(m,1H),7.22-7.30(m,6H) ,<br>
8.22(d,1H,J=6.9),8.71(d,1H,J=4.8).<br>
MALDI-TOF-MS :C25H37N3O7(M+Na) + , 514 . 2530 .Found: 514 . 2944 .<br>
[α]D25+13.9° (c 0.20,DMSO)<br>
Example 18<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 8-methoxy-3,6-dioxaoctyl ester<br>
(Compound 18)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 5 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
8-methoxy-3,6-dioxaoctyl ester.<br>
M.p. 116.0-117.2°C.<br>
1H-NMR(300MHz,DMSO-d6) δ 0 . 58 (m, 2H) , 0 . 65 (m, 2H) , 0 . 83 (d, 3H,<br>
J=7.8),0.85(d,3H,J=6.9),1.35(m,2H),1.57(m,1H),2.73-2.86<br>
(m,2H) ,3.11(m,1H),3.24(s,3H),3.44(m,2H),3.51(m,6H),3.56(t,2<br>
H, J=4.7),4.04(m,3H),5.17(m,1H),7.22-7.31(m,6H),8.25(d,1H,J=<br>
6.9),8.73(d,1H,J=5.1).<br>
MALDI-TOF-MS:C27H4iN3O8(M+Na) +, 558 . 2792 ,Found: 558 .2111.<br>
[α]D25+2.5° (c 0.20.DMSO)<br>
Example 19<br>
((1S)-1-((((1S)-1-Benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 111-methoxy-3 , 6 , 9-trioxaundecanyl<br>
ester (Compound 19)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 6 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
111-methoxy-3,6,9-trioxaundecanyl ester.<br>
M.p. 97.5-98.5°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.54-0.66(m,4H),0.81-0.86(m,6H),<br>
1.32-1.37(m,2H),1.56(m,1H),2.73(m,1H),2.82(dd,1H,J=14.0,9.2<br>
),3.11(dd,1H,J=14.1,4.2),3.24(s,3H),3.41-3.44(m.2H),3.50-3.<br>
51(m,10H),3.54-3.57(m,2H),3.99-4.08(m,3H),5.16(m,1H),7.22-7<br>
.31(m,6H),8.25(d,1H,J=7.2),8.73(d,1H,J=5.1).<br>
MALDI-TOF-MS :C29H45N3O9(M+Na) + , 602 . 3054 .Found: 602 . 3427 .<br>
[α]D25+6.9° (c 0.20,DMSO)<br>
Example 20<br>
((1S)-1-((((lS}-1-Benzyl-2,3-dioxo-3-<br>
(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 14-methoxy-3,6,9,12-tetraoxa-<br>
tetradecanyl ester (Compound 20)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 7 and 9 in place<br>
of the compounds of Reference Examples 1 and 7 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
( (IS) -1- ( ( ( (,lS)-1-benzyl-3-cyclopropylamino-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
14-methoxy-3,6,9,12-tetraoxatetradecanyl ester.<br>
M.p. 98.5-99.9°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.58(m,2H),0.65(m,2H),0.83 (d,3H,<br>
J=6.9),0.85(d,3H,J=7.8),1.35(m,2H),1.57(m,1H),2.73-2.86<br>
(m,2H),3.11(m,1H),3.24(s,3H),3.42(m,2H),3.51(m,14H),3.56<br>
(t.2H,J=3.3),4.04(m,3H),5.17(m,1H),7.22-7.30(m,6H),8.24( d, 1<br>
H,J=6.9),8.72(d,1H,J=4.5).<br>
MALDI-TOF-MS:C31H49N3O10(M+Na)+ , 646 . 3316 ,Found: 646 . 3404 .<br>
Example 21<br>
((1S)-1-((((1S)-2,3-Dioxo-1-(2-methylpropyl)-3-(2-<br>
phenoxyethyl)aminopropyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 2-methoxyethyl ester (Compound 21)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compound of Reference Examples 18 in place of<br>
the compound of Reference Example 8, the title compound was<br>
obtained as colorless crystals, via ((1S)-1-((((1S)-2-<br>
hydroxy-1- ( 2-methylpropyl) -3-oxo-3- (2-<br>
phenoxyethyl) aminopropyl) amino) carbonyl) - 3 -<br>
methylbutyl)carbamic acid 2-methoxyethyl ester.<br>
M.p. 99.7-100.5°C<br>
1H-NMR(300MHz,DMS0-d6) δ 0.88(dd,12H,J=12.0,6.3),1.35-1.54<br>
(m,4H),1.58-1.75(m,2H),3.25(s,3H),3.46-3.53 (m, 4H) ,4.03-4.07<br>
(m,5H),5.06(m,1H),6.91-6.95(m,3H),7.26-7.31(m,3H),8.15(d,lH<br>
,J=7.2),8.81(t,1H,J=5.9).<br>
MALDI-TOF-MS :C25H39N3O7(M+H)+ , 494 . 2866 , Found: 494 . 2967 .<br>
Example 22<br>
((1S)-1-("( ((1S)-2,3-Dioxo-1-(2-methylpropyl)-3-(2-<br>
phenoxyethyl)aminopropyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester<br>
(Compound 22)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 4 and 18 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-!-((((1S)-2-hydroxy-1-(2-methylpropyl)-3-oxo-3-(2-<br>
phenoxyethyl)aminopropyl)amino)carbonyl) - 3 -<br>
methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester.<br>
M.p. 53.5-54.1°C<br>
1H-NMR(300MHz,DMSO-d6) δ 0.87(dd,12H,J=12.2,6.5),1.35-1.54<br>
(m,4H),1.58-1.75(m,2H),3.24(s,3H),3.41-3.45(m,2H),3.47-3.57<br>
(m,6H),4.03-4.07(m,5H),5.06(m,1H),6.91-6.96(m,3H),7.26-7.31<br>
(m,3H),8.17(d,1H,J=6.9),8.83(t,1H,J=5.7).<br>
MALDI-TOF-MS :C27H43N3O8(M+H) + , 538 . 3128 , Found: 538 . 3140 .<br>
Example 23<br>
((1S)-1-((((lRS)-3-amino-1-benzyl-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
5-methoxy-3-oxapentyl ester (Compound 23)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 4 and 19 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((lRS)-3-amino-1-benzyl-2-hydroxy-3-oxo-<br><br>
propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-<br>
methoxy-3-oxapentyl ester.<br>
1H-NMR(300MHz,DMSO-d6) δ0 . 77(d,3H,J=6.3),0.83(d,1.5H,J=6.6),<br>
0.86(d,1.5H,J=6.9),1.05-1.63(m,3H),2.68-2.85(m,1H),3.12(m,l<br>
H),3.23(s,3H),3.42(m,2H),3.51-3.56(m,4H),4.03(m,3H),5.22(m,<br>
1H),7.21-7.31(m,6H),7.81(d,1H,J=14),8.06(d,1H,J=18),8.19(d,<br>
0.5H,J=6.9),8.26(d,0.5H,J=7.5).<br>
Example 24<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-dioxo-<br>
propyl)amino)carbonyl)-3-methylbutyl)carbamic	acid<br>
2-(pyridin-2-yl)ethyl ester (Compound 24)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 20 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl}carbamic acid<br>
2-(pyridin-2-yl)ethyl ester.<br>
1H-NMR(300MHz,DMSO-d6) δ 0.58-0.66(m,4H),0.83(t,6H,J=7.1),<br>
1.31-1.35(m,2H),1.53(m,1H),2.74(m,1H).2.81(dd,1H,J=14.1,9.3<br>
),3.02(t,2H,J=6.3),3.11(dd,1H,J=14.0,4.1),4.01(m,1H),4.28-4<br>
.32(m,2H),5.17(m,1H),7.14-7.34(m,8H),7.75(t,1H,J=6.8),8.23{<br>
d,1H,J= 7.2),8.51(d,1H,J=4.2),8.71(d,1H,J=4.5).<br><br>
Example 25<br>
( (1S)-1-((((1S)-1-Benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
2-(6-methylpyridin-2-yl)ethyl ester (Compound 25)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 21 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
( ((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2-hydroxy-3-<br>
oxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
2-(6-methylpyridin-2-yl)ethyl ester.<br>
M.p. 162.0-163.6°C<br>
1H-NMR (300 MHz, DMSO-d6) δ 0.54-0.66 (m, 4H) , 0.76-0.86' (m,<br>
6H), 1.54 (m, 1H), 2.43 (s, 3H), 2.73-2.86 (m, 2H), 2.96 (t,<br>
2H, J = 6.5), 3.11 (m, 1H), 4.03 (m, 1H), 4.21-4.34 (m, 2H),<br>
5.17 (m, 1H), 7.07-7.30 (m, 8H), 7.58 (t, 1H, J = 7.7), 8.23<br>
(d, 1H, J = 6.9), 8.72 (d, 1H, J = 4.8).<br>
Example 26<br>
((1S)-1-((((1S)-1-Benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl) amino) carbonyl) - 3 -methylbutyl) carbamic acid<br>
2-(5-ethylpyridin-2-yl)ethyl ester (Compound 26)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 22 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2-hydroxy-3-o<br>
xopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-(5-ethylpyridin-2-yl)ethyl ester.<br>
M.p. 119. 9-121. 0°C<br>
1H-NMR (300 MHz, DMS0-d6) δ 0.58-0.66 (m, 4H) , 0.75-0.85 (m, 6H) ,<br>
1.17 (t, 3H, J = 7.7), 1.33-1.36 (m, 2H), 1.53 (m, 1H), 2.58<br>
(dd, 2H, J = 15.5, 8.3), 2.74-2.85 (m, 2H) , 2.94-2.98 (m, 2H) ,<br>
3.12 (m, 1H), 4.04 (m, 1H), 4.28-4.29 (m, 2H), 5.17 (m, 1H),<br>
7.13-7.26 (m, 7H), 7.55 (d, 1H, J = 8.1), 8.22-8.35 (m, 2H) ,<br>
8.75 (m, 1H).<br>
Example 27<br>
((1S)-1-((((1S)-1-Benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-tert-butoxyethyl ester (Compound 27)<br><br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 23 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-tert-butoxyethyl ester.<br>
1H-NMR (300 MHz, DMSO-d6) δ 0.58 (m, 2H) , 0.65 (m, 2H) , 0.83<br>
(d, 3H, J = 7.5), 0.85 (d, 3H, J = 6.9), 1.12 (s, 9H) , 1.35 (m,<br>
2H), 1.57 (m, 1H), 2.74 (m, 1H), 2.82 (m, 1H), 3.11 (m, 1H) ,<br>
3.45 (m, 2H), 3.98 (m, 3H), 5.17 (m, 1H), 7.24 (m, 6H), 8.23<br>
(d, 1H, J = 6.6), 8.71 (d, 1H, J = 4.8).<br>
Example 28<br>
((1S)-1-((((1S)-1-Benzyl-3-(cyclopropylamino)-2,3-<br>
dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-isopropoxyethyloxyl ester (Compound 28)<br><br>
Following the reaction in an analogous manner to Example<br>
1 and using the compounds of Reference Examples 24 and 9 in place<br>
of the compounds of Reference Examples 1 and 8 respectively,<br>
the title compound was obtained as colorless crystals, via<br>
((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2-hydroxy-3-<br>
oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid<br>
2-isopropoxyethyl ester.<br><br>
1H-NMR (300 MHz, DMSO-d6) δ 0.58 (m, 2H) , 0.65 (m, 2H) , 0.83<br>
(d, 3H, J = 7.2), 0.85 (d, 3H, J = 6.9), 1.07 (d, 6H, J = 5.7),<br>
1.35 (m, 2H), 1.57 (m, 1H) , 2.74 (in, 1H) , 2.82 (m, 1H) , 3.12<br>
(m, 1H) , 3.50 (m, 2H) , 3.55 (m, 1H) , 4.01 (m, 3H) , 5.17 (m, 1H) ,<br>
7.24 (m, 6H), 8.22 (d, 1H, J = 6.9), 8.71 (d, 1H, J = 3.6).<br>
Test Example 1<br>
(1) Measurement of inhibitory activity against µ-calpain and<br>
m-calpain<br>
The inhibitory activity against [X-calpain and m-calpain<br>
was assayed according to the method described in Anal. Biochem.<br>
1993, vol. 208, p. 387-392. That is, to 2.5 µL of a DMSO solution<br>
containing a varying concentration of the test sample in a<br>
96-well plate was added 200 µL of a reaction solution containing<br>
0.5 mg/mL casein, 50mM Tris-HCl buffer (pH 7.4), 20 mM<br>
dithiothreitol and 1.0 nmol µ-calpain (derived from human red<br>
blood cells; available from Cosmo Bio Co. Ltd.) or m-calpain<br>
(derived from porcine kidney; available from Cosmo Bio Co. Ltd. ) .<br>
After 20mM aqueous calcium chloride (50 µL) was added thereto,<br>
the mixture was incubated at 30°C for 60 minutes. Then, 100<br>
µL of the reaction solution was transferred to another 96-well<br>
plate, and purified water (50 µL) and 50% aqueous solution (100<br>
µL) of Protein Assay Dye Reagent (available from Bio-Rad<br>
Laboratories, Inc.; catalogue No. 500-600) were added thereto.<br>
The reaction mixture was allowed to stand at room temperature<br>
for 15 minutes, and its absorbance was measured at 59 5 nm.<br>
The absorbance of a reaction mixture prepared in the same<br>
manner as mentioned above, except that a DMSO solution contained<br>
no sample, was used as a control value, and that of a reaction<br><br>
mixture prepared in the same manner as mentioned above, except<br>
that 1 mM aqueous EDTA solution (50 µL) was used in place of<br>
20 mM aqueous calcium chloride, was used as a blank value.<br>
Inhibition rate was calculated by means of the following<br>
equation, and the concentration required for 50% inhibition<br>
(IC50) was determined.<br>
Inhibition rate (%)={1-(measured value minus blank value)/<br>
(control value minus blank value)} x 100<br>
The calpain inhibitory activities are shown in Table 1,<br>
which indicates that the compounds of the present invention<br>
strongly inhibited activities of µ-calpain and m-calpain.<br><br><br><br>
Test Example 2: Solubility<br>
Solubility of the compounds of the present invention in<br>
10 mM phosphate buffer (pH 7.0) was measured. The solubility<br>
of the compounds of the present invention is shown in Table 2.<br>
Table 2<br><br>
Test Example 3: Permeability test with Caco-2 cells<br>
1 x 105/cm2 of Caco-2 cells (Catalog No. HTB-37, available<br>
from ATCC, passage number: 56) were seeded into a culture insert<br>
(polycarbonate porous filter: FALCON(trade mark) 3096, pore<br>
diameter 3 µm; area 0.31 cm2), and incubated for 22 days under<br>
the conditions of 37°C and 5% CO2 to prepare a monolayer cell.<br>
As a culture medium for the incubation, Dulbecco's modified<br>
Eagle's minimum essential medium (GIBCO BRL) supplemented with<br>
10% fetal calf serum (GIBCO BRL), antibiotic-antimycotic<br>
mixture, liquid (GIBCO BRL) , non-essential amino acid solution.<br><br>
(GIBCO BRL) and 2 mmol/L L-glutamine (GIBCO BRL) was used. The<br>
cells were preincubated in advance in a Hanks' Balanced Salt<br>
Solution (apical membrane side: pH 6.5, basolateralt membrane<br>
side: pH 7.4) containing no sample or no control substance at<br>
37°C for one hour. A Hanks' Balanced Salt Solution (pH 6.5,<br>
37°C) containing a 10 pm sample or a control substance was run<br>
to the apical membrane side (250 µL) , and the sample (950 µL)<br>
permeated through the basolateral membrane was quantified.<br>
That is , 500 µL was collected from the basolateral membrane side<br>
after one or two hours, and the permeation coefficient was<br>
measured. Propranolol was used as a positive control, and<br>
14C-mannitol was used as a negative control. LC-MS/MS was used<br>
for quantitative analysis of samples, and a liquid<br>
scintillation counter was used for quantitative analysis of<br>
14C-mannitol.<br>
An amount of the sample or the control substance which<br>
had been permeated through the basolateral membrane of Caco-2<br>
monolayer cells was determined, and apparent permeation<br>
coefficient (Papp) was calculated according to the formula:<br>
PaPP= (δQ/δt) x (1/60AC0).<br>
Papp : apparent permeation coefficient (cm/sec)<br>
δQ/5t : permeation velocity (pmol/min)<br>
 A : area of monolayer cell = 0.33 cm2<br>
C0 : initial concentration at apical membrane side<br>
(pmol/mL)<br>
Test Example 4 : Measurement of partition coefficient using I AM<br>
column<br>
Analysis by HPLC system was carried out under the<br><br>
conditions given below, and retention time of each substance<br>
was measured.<br>
Column: IAM fast screening mini-column (Regis Technologies,<br>
Inc.)<br>
Mobile phase: Dulbecco's phosphate buffer (pH 7.4)<br>
Detection wavelength: 250 nm<br>
Column temperature: room temperature<br>
Injection amount: 5.0 to 20 µL<br>
Flow rate: 0.5 mL/min<br>
Sample solution: 5 mg of sample was dissolved in 100 µL of<br>
acetonitrile, and a mobile phase was added to make 1 mL<br>
of a sample solution.<br>
The measured value was inserted into the following<br>
formula, and the partition coefficient (K'IAM) was calculated,<br>
k' IAM = (tR-to)/t0<br>
t0: retention time of the peak derived from acetonitrile<br>
tR: retention time of the peak of the sample<br>
The membrane permeability of the compounds of the present<br>
invention was evaluated on the basis of the partition<br>
coefficient (K'IAM) calculated from the permeability through<br>
Caco-2 cell membrane (PapP (apical membrane side -&gt; basolateral<br>
membrane side)) and/or the correlated retention time in IAM<br>
column analysis.<br>
The results of Caco-2 cell permeability assay showed that<br>
all compounds measured showed Papp = 10-6 or higher, a value<br>
indicating that the permeability is not a rate-limiting step<br>
in absorption. Also, an IAM column analysis revealed that the<br><br>
compound tested showed k' IAM = 0.7 or higher, which was considered<br>
to be equivalent to Caco-2 cell permeability of Papp=10-6.<br>
According to these results, it was considered that oral<br>
administration would not cause any problem on membrane<br>
permeability in the digestive tract during absorption.<br><br>
Test Example 5: Measurement of transportation rate into blood<br>
The compound of the present invention was administered<br>
orally to Macaca fascicularis (crab-eating monkey) at a dose<br>
of 10 mg/kg. The blood was collected with the lapse of time,<br>
and the concentration of each compound in the plasma was<br>
measured. The maximum plasma concentration (Cmax) and the area<br>
under the blood concentration-time curve (AUC) were shown in<br>
Table 4.<br>
When the compound of the present invention was<br>
administered orally, it was transported into the blood with a<br>
higher enzyme inhibitory activity (IC50) than that shown in Test<br><br>
Example 1, elucidating that the compound of the present<br>
invention has excellent pharmakokinetics.<br>
Table 4<br><br>
Experimental Example 6 Effect on rat retinal ischemia<br>
reperfusion injury<br>
Male SD rats (body weight: 150-200 g, purchased from<br>
Charles River Japan, Inc.) were used. For anesthesia, a mixture<br>
of equivalent amounts of 50 mg/mL ketamine injection and 20<br>
mg/mL xylazine injection was administered intramuscularly at<br>
1.0 mL/Kg body weight into the femora of the rats 15 minutes<br>
before ischemia. To achieve ischemia, the optic nerve<br>
including central retinal artery was ligated using a Sugita Clip<br>
minitype (No. 98), and the blood flow was blocked for 55 minutes .<br>
Such ligation was released 55 minutes after the above ligation,<br>
and blood flow was made to run again into retina (hereinafter,<br>
referred to as ischemia reperfusion). For normal group,<br>
central retinal artery was only exposed and ischemia was not<br>
set up. After 7 days from reperfusion in ischemia, a tissue<br>
specimen was prepared. For preparation of the tissue specimen,<br>
an excess amount of pentobarbital solution was<br><br>
intraperitoneally administered to sacrifice the animal, and<br>
eyeball was enucleated. The enucleated eyeball was dipped and<br>
fixed for 24 hours in a fixing solution of 2% paraformaldehyde<br>
and 2.5% glutaraldehyde (0.1 Mphosphate buffer, pH 7 . 4) . After<br>
fixing, a paraffin embedded block of eyeball was prepared, and<br>
such a paraffin embedded eyeball was sliced with a microtome<br>
in a thickness of 3 µm at the section passing through the center<br>
of the optic disc. The sections were stained with hematoxylin<br>
and eosin (HE) in a conventional manner. The stained sections<br>
were observed under an optical microscope, and ganglion cells<br>
of retina per 0.25 mm width of retina section at 1-2 mm from<br>
the center of the optic disc were counted.<br>
Compound 17 was used as a drug to be tested. A solution<br>
obtained by dissolving sodium carboxymethylcellulose in<br>
distilled water to a concentration of 0.5% (CMC solution) was<br>
orally administered to the control group, and a solution<br>
obtained by suspending Compound 17 in a CMC solution at 1.0 %,<br>
such that Compound 17 was administered at 100 mg/Kg body weight,<br>
was orally administered to the drug group, both at 15 minutes<br>
before start of ischemia and immediately after release from<br>
ischemia (Compound 17 administration group). A CMC solution<br>
was administered to control group and normal group in a similar<br>
manner.<br>
The results thereof are shown in Fig. 1. The ganglion<br>
cell count decreased to about 1/4 of that of the normal group<br>
(control group) due to ischemia reperfusion. In contrast.<br>
Compound 17 administration (drug group) significantly<br>
suppressed the decrease due to ischemia reperfusion in the<br>
ganglion cell count. The above results suggest that Compound<br><br>
17 of the present invention has an effect to improve retinal<br>
ischemic disorder.<br><br>
Compound 4, starch and lactose were blended well, and<br>
formulated into granules for tableting according to the wet<br>
granule tableting method. After addition of magnesium<br>
stearate, the granules were compressed to make 400 tablets . The<br>
tablets were, if required, coated with an enteric coating agent<br>
(methacrylic acid copolymer).<br><br>
The above components were mixed under sterile conditions<br>
according to the conventional method to prepare eye drops.<br>
Formulation Example 3: Injection<br><br>
Compound 17	100 mg<br>
Sodium chloride	900 mg<br>
IN Sodium hydroxide	q.s.<br>
Distilled water for injection total volume 100 mL<br><br>
The above components were mixed under sterile conditions<br>
according to the conventional method to prepare an injection<br>
preparation.<br>
 Industrial Applicability<br>
Since the compounds of the formula (I) of the present invention<br>
have excellent calpain inhibitory activity and good oral<br>
absorbability, they are useful as a prophylactic and<br>
therapeutic agent for various diseases related to calpain such<br>
 as ischemic disease, immunologic disease, multiple sclerosis<br>
Alzheimer's disease, osteoporosis, diseases caused by brain<br>
tissue damage, cataract, glaucoma, retinal disease,<br>
retinochoroiditis (diabetic retinopathy, retinal vein<br>
occulusion, macular degeneration, retinitis pigmentosa,<br>
 hypertensive retinopathy, retinal detachment, etc.),<br>
posterior eyeball complications due to photocoagulation or a<br>
disease involving neovascularization.<br><br><br>
WE CLAIM:<br>
1.	A compound represented by the formula (I)<br><br>
wherein R1 is<br>
(1)	a group represented by the formula (IIb) in which n is an integer of 2 to 5,<br><br>
(2)	a straight or branched C1-6 alkyl substituted by a pyridyl group optionally having a C1-3 alkyl<br>
substituent on the pyridine ring, or<br>
(3)	a tetrahydrofuranyl group or a tetrahydropyranyl group;<br>
R2 is a straight or branched C1-6 alkyl, optionally substituted by a phenyl; and<br>
R3 is hydrogen, a straight or branched C1-6 alkyl or is selected from the group consisting<br>
of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.<br>
2.	The compound as claimed in Claim 1, wherein R1 is a group of the<br>
formula (IIb)<br><br>
in which n is an integer of 2 to 5.<br><br>
3.	The compound as claimed in Claim 1, wherein R3 is cyclopropyl.<br>
4.	The compound as claimed in claim 1 selected from the group consisting of<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester,<br>
((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 8-methoxy-3,6-dioxaOctyl ester,<br>
((1S)-1 -((((1S)-1 -benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-<br>
methylbutyl)carbamic acid 11-methoxy-3,6,9-trioxaundecanyl ester, or<br>
((1 S)-1-((((1S)-1 -benzyl-3-(cyclopropyIamino)-2,3-dioxopropyl)amino)carbonyl)-3 -<br>
methylbutyl)carbamic acid 2-(pyridin-2-yl)ethyl ester.<br>
5.	A medicament comprising the compound as claimed in Claim 1.<br><br><br>
6.	The compound as claimed in Claim 1, which is ((1S)-1-((((1S)-1-<br>
benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-<br>
methoxy-3-oxapentyl ester.<br><br><br>
(54) Title: ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF<br><br>
(57) Abstract: The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA)<br>
(wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl<br>
optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a<br>
fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain<br>
inhibitory aclivity.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBhYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBjbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBjb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBkZXNjcmlwdGlvbihjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBkcmF3aW5ncy5wZGY=" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBmb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBmb3JtLTMucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBmb3JtLTUucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBpbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBpbnRlcm5hdGlvbmFsIHNlYXJjaCBhdXRob3JpdHkgcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 international search authority report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBwY3QgZm9ybS5wZGY=" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 pct form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNiBwcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006 priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNi1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNi1jb3JyZXNwb25kZW5jZSBvdGhlcnMtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006-correspondence others-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNi1jb3JyZXNwb25kZW5jZS0xLjIucGRm" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006-correspondence-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNi1mb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzNzkta29sbnAtMjAwNi1mb3JtLTMtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01379-kolnp-2006-form-3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LSgwNC0wMy0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-(04-03-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LSgwNC0wMy0yMDEzKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-(04-03-2013)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LSgwNC0wMy0yMDEzKS1GT1JNLTEzLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-(04-03-2013)-FORM-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LSgwNC0wMy0yMDEzKS1QQS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-(04-03-2013)-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LSgwNS0xMS0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-(05-11-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LSgxMC0wOS0yMDEyKS1FeGFtaW5hdGlvbiBSZXBvcnQgUmVwbHkgUmVjaWV2ZWQucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-(10-09-2012)-Examination Report Reply Recieved.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUFCU1RSQUNULTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-ABSTRACT-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUFNRU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-AMENDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNBTkNFTExFRCBET0NVTUVOVFMucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CANCELLED DOCUMENTS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNBTkNFTExFRCBQQUdFUy5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CANCELLED PAGES.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNMQUlNUy0xLjAucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CLAIMS-1.0.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNMQUlNU18xLjEucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CLAIMS_1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFLTEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CORRESPONDENCE-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LURFU0NSSVBUSU9OIENPTVBMRVRFLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-DESCRIPTION COMPLETE-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LURSQVdJTkdTLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-DRAWINGS-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMTMucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMy0xLjIucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 3-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMy0xLjMucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 3-1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUZPUk0gMy0xLjQucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-FORM 3-1.4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtRFJBV0lOR1MucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-DRAWINGS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtRk9STSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtRk9STSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtTEVUVEVSIFBBVEVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-LETTER PATENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LUdSQU5URUQtU1BFQ0lGSUNBVElPTi1DT01QTEVURS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-GRANTED-SPECIFICATION-COMPLETE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LU9USEVSUy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-OTHERS-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-PETITION UNDER RULE 137-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-REPLY TO EXAMINATION REPORT-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC0xLjIucGRm" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-REPLY TO EXAMINATION REPORT-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM3OS1LT0xOUC0yMDA2LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1379-KOLNP-2006-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDEzNzkta29sbnAtMjAwNi5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-01379-kolnp-2006.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="256469-novel-substituted-sulfamate-anticonvulsant-derivatives.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="256471-process-for-converting-primary-amidoalcohols-to-amidocarboxylic-acids-in-high-yeild.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>256470</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1379/KOLNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>26/2013</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>28-Jun-2013</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>20-Jun-2013</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>23-May-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SENJU PHARMACEUTICAL CO., LTD.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>5-8, HIRANOMACHI 2-CHOME, CHUO-KU, OSAKA-SHI, OSAKA, 541-0046</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SHIRASAKI, YOSHIHISA</td>
											<td>7-26-202, KARIBADAI 3-CHOME, NISHI-KU, KOBE-SHI, HYOGO 651-2272</td>
										</tr>
										<tr>
											<td>2</td>
											<td>NAKAMURA, MASAYUKI</td>
											<td>16-10, IZUMIDAI 3-CHOME, KITA-KU, KOBE-SHI, HYOGO 651-1141</td>
										</tr>
										<tr>
											<td>3</td>
											<td>INOUE, JUN</td>
											<td>26-7, SHIRAKAWADAI, 1-CHOME, SUMA-KU, KOBE-SHI, HYOGO 654-0103</td>
										</tr>
										<tr>
											<td>4</td>
											<td>MIYASHITA, HIROYUKI</td>
											<td>17-19-602, KUHONJI 3-CHOME, KUMAMOTO-SHI, KUMAMOTO, 862-0976</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 271/22</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/JP2004/018692</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-12-08</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>2003-415764</td>
									<td>2003-12-12</td>
								    <td>Japan</td>
								</tr>
								<tr>
									<td>2</td>
									<td>2004-234164</td>
									<td>2004-08-11</td>
								    <td>Japan</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/256470-alpha-ketoamide-derivative-and-production-method-and-use-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:31:05 GMT -->
</html>
